#BEGIN_DRUGCARD DB03909

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C11H18N5O12P3

# Chemical_IUPAC_Name:
({[({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}methyl)phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate

# HET_ID:
ACP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H18N5O12P3/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(27-11)1-26-31(24,25)28-30(22,23)4-29(19,20)21/h2-3,5,7-8,11,17-18H,1,4H2,(H,22,23)(H,24,25)(H2,12,13,14)(H2,19,20,21)/t5-,7-,8+,11+/m0/s1

# InChI_Key:
InChIKey=UFZTZBNSLXELAL-WOIOKPISSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3909

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
505.2082

# Molecular_Weight_Mono:
505.016480601

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1JBV

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.1

# Predicted_LogS:
-2.1

# Predicted_Water_Solubility:
4.45e+00 g/l

# Primary_Accession_No:
DB03909

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936826

# PubChem_Substance_ID:
46506243

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00416

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC=NC2=C1N=CN2[C@@H]1O[C@@H](CO[P@@](O)(=O)O[P@@](O)(=O)CP(O)(O)=O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:45 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
BX842572

# Drug_Target_10_GenBank_ID_Protein:
41352723

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
pknB

# Drug_Target_10_Gene_Sequence:
>1881 bp
CTACTGGCCGAACCTCAGCGTGATGATGCCGTCCCGGTTGACGCCGGTCCCCGCCGGCGG
GTTTTGATAGACGACCCGGTTGTGTTGGGAGCCACCGGCGTCGACGTCGGCCCCTTTGTC
GAGCATCCCGGTCCAGCCCAGCGCGCGCAATCGTGGTTCGGCGTCGACCCAGAACATGCC
GGATAGGTCGGGCATGACGAATTGGTTGCCCTTGGACACCTGTAGTTCGATGACTGAATC
GACCGGAACTGTGGTGCCTGCGGGTGGATTGGTGCCGGTCACCTCGCCGGCGGGACGGGG
GCTGTCCACCGAGGCCTGACTGAATTTGGTGAAGCCGTAGACGTTGAGGTTCTTCTGCGC
CACGTCGACGGTCTGGCCCGCGACATCGGGAATGTCTTTGGTCGCCGGACCAGAGCCAAC
GATGATGATGACCACATTGGTGATGGCCGACGTCTGGTTGGCTGGCGGGTTGGTCCCGAT
GACCTTGCCCACCAGTTCCGGGGTGGACGGCGAATTCGCTTGCTTGAAGCGGCCGAATCC
GGCGGCAGTCAGTTTCTTGACCGCTTCGGCGTATGTCAGCGTGGAGACGTCGGGTATTTC
GCGTTGCTCGGGTCCGGTGGACACGTTGACTGTGATCTCGTCGCCTGCACTCACCGACGT
GTTGGCGGCCGGGTCGGTGCCGATAACGTGGTCCGGTGGGATTGTCGAGTCCGGCTTCTG
CAAGGTGCGGATTTTGAAGCCCCGGTTTTGCAGTGTGGCGATGGCGTCGGCGGAGGATTG
ACCCCGAACGTCGGGAACTTGAACGTCGCGGGTGATGCCGCCGAACGTGTTGATGGCGAT
GGTTACCACGACGGTCAGCACAGCGAGCACGGCGACCACCGCAACCCAACGGCCCACCGA
ACCGATGCTGCGGTCACGGTCGGTGTCGTCTAAGTCCTGGCGTGGTAGCGGATCGGTGCG
CGGACCGCTAAGGTTGCCGGCCGCAGACGACAGCAGCGAGGTCCGCTCGGCATCGGTGAG
CACTTTGGGCGCCTCGGGCGGCTCACCGTTGTGCACGCGGACCAGGTCGGCGCGCATCTC
CGCCGCTGTCTGATAGCGGTTTTCCGGATTTTTGGCCAGCGCCTTGAGAACGACGGCGTC
CAGGTCGGCGGAGAGGCCTTCGTGCCGCGCCGAAGGTGGGATCGGGTCTTCGCGCACATG
TTGGTAGGCAACCGAGACGGGTGAGTCGCCGGTGAAAGGTGGCTCCCCGGTGAGGACTTC
ATAAAGAACACAGCCCAAGGAATAGACATCGGATCGGGCGTCGACGGAATCACCCCGGGC
CTGTTCGGGTGACAGGTACTGCGCCGTGCCGATCACTGCTGCGGTCTGGGTCACGCTGTT
GCCGCTGTCGGCAATGGCGCGGGCGATGCCGAAATCCATCACCTTTACTGCATTGGTCGC
GCTGATCATGATGTTCGCCGGCTTGACGTCACGGTGGATGATTCCGTTCTGATGACTGAA
GTTCAGCGCTTGGCAGGCGTCGGCGATGACCTCGATGGCGCGTTTGGGCGTCATCGGCCC
TTCGGTGTGGACAATGTCGCGCAGGGTAACGCCGTCGACGTATTCCATGACGATGTAGGG
CAATGGCCCGGCGGGCGTTTCGGCTTCACCGGTGTCGTAGACCGCGACGATTGCAGGGTG
GTTCAATGCCGCGGCGTTTTGCGCCTCACGCCGGAAGCGAAGGTAAAAACTGGGATCGCG
GGCTAGATCAGCGCGCAGCACCTTGACCGCAACGTCGCGGTGCAACCGGAGGTCGCGGGC
CAGGTGGACCTCGGACATGCCCCCAAATCCAAGGATTTCGCCAAGTTCGTAGCGGTCGGA
CAGGTGGGAAGGGGTGGTCAT

# Drug_Target_10_General_Function:
Involved in penicillin binding

# Drug_Target_10_General_References:
12218036	Fleischmann RD, Alland D, Eisen JA, Carpenter L, White O, Peterson J, DeBoy R, Dodson R, Gwinn M, Haft D, Hickey E, Kolonay JF, Nelson WC, Umayam LA, Ermolaeva M, Salzberg SL, Delcher A, Utterback T, Weidman J, Khouri H, Gill J, Mikula A, Bishai W, Jacobs Jr WR Jr, Venter JC, Fraser CM: Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol. 2002 Oct;184(19):5479-90.
9634230	Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE 3rd, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998 Jun 11;393(6685):537-44.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
2878

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
66510

# Drug_Target_10_Name:
Probable serine/threonine-protein kinase pknB

# Drug_Target_10_Number_of_Residues:
626

# Drug_Target_10_PDB_ID:
1MRU

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00069	Pkinase
PF03793	PASTA

# Drug_Target_10_Protein_Sequence:
>Probable serine/threonine-protein kinase pknB
MTTPSHLSDRYELGEILGFGGMSEVHLARDLRLHRDVAVKVLRADLARDPSFYLRFRREA
QNAAALNHPAIVAVYDTGEAETPAGPLPYIVMEYVDGVTLRDIVHTEGPMTPKRAIEVIA
DACQALNFSHQNGIIHRDVKPANIMISATNAVKVMDFGIARAIADSGNSVTQTAAVIGTA
QYLSPEQARGDSVDARSDVYSLGCVLYEVLTGEPPFTGDSPVSVAYQHVREDPIPPSARH
EGLSADLDAVVLKALAKNPENRYQTAAEMRADLVRVHNGEPPEAPKVLTDAERTSLLSSA
AGNLSGPRTDPLPRQDLDDTDRDRSIGSVGRWVAVVAVLAVLTVVVTIAINTFGGITRDV
QVPDVRGQSSADAIATLQNRGFKIRTLQKPDSTIPPDHVIGTDPAANTSVSAGDEITVNV
STGPEQREIPDVSTLTYAEAVKKLTAAGFGRFKQANSPSTPELVGKVIGTNPPANQTSAI
TNVVIIIVGSGPATKDIPDVAGQTVDVAQKNLNVYGFTKFSQASVDSPRPAGEVTGTNPP
AGTTVPVDSVIELQVSKGNQFVMPDLSGMFWVDAEPRLRALGWTGMLDKGADVDAGGSQH
NRVVYQNPPAGTGVNRDGIITLRFGQ

# Drug_Target_10_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_10_SwissProt_ID:
P0A5S4

# Drug_Target_10_SwissProt_Name:
PKNB_MYCTU

# Drug_Target_10_Synonyms:
EC 2.7.11.1

# Drug_Target_10_Theoretical_pI:
5.08

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Cytoplasm

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
M13169

# Drug_Target_11_GenBank_ID_Protein:
Not Available

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
rbsK

# Drug_Target_11_Gene_Sequence:
Not Available

# Drug_Target_11_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_11_General_References:
10438599	Sigrell JA, Cameron AD, Mowbray SL: Induced fit on sugar binding activates ribokinase. J Mol Biol. 1999 Jul 30;290(5):1009-18.
3011794	Hope JN, Bell AW, Hermodson MA, Groarke JM: Ribokinase from Escherichia coli K12. Nucleotide sequence and overexpression of the rbsK gene and purification of ribokinase. J Biol Chem. 1986 Jun 15;261(17):7663-8.
7686882	Burland V, Plunkett G 3rd, Daniels DL, Blattner FR: DNA sequence and analysis of 136 kilobases of the Escherichia coli genome: organizational symmetry around the origin of replication. Genomics. 1993 Jun;16(3):551-61.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9385653	Sigrell JA, Cameron AD, Jones TA, Mowbray SL: Purification, characterization, and crystallization of Escherichia coli ribokinase. Protein Sci. 1997 Nov;6(11):2474-6.
9519409	Sigrell JA, Cameron AD, Jones TA, Mowbray SL: Structure of Escherichia coli ribokinase in complex with ribose and dinucleotide determined to 1.8 A resolution: insights into a new family of kinase structures. Structure. 1998 Feb 15;6(2):183-93.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
3669

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
32291

# Drug_Target_11_Name:
Ribokinase

# Drug_Target_11_Number_of_Residues:
309

# Drug_Target_11_PDB_ID:
1GQT

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00294	PfkB

# Drug_Target_11_Protein_Sequence:
>Ribokinase
MQNAGSLVVLGSINADHILNLQSFPTPGETVTGNHYQVAFGGKGANQAVAAGRSGANIAF
IACTGDDSIGESVRQQLATDNIDITPVSVIKGESTGVALIFVNGEGENVIGIHAGANAAL
SPALVEAQRERIANASALLMQLESPLESVMAAAKIAHQNKTIVALNPAPARELPDELLAL
VDIITPNETEAEKLTGIRVENDEDAAKAAQVLHEKGIRTVLITLGSRGVWASVNGEGQRV
PGFRVQAVDTIAAGDTFNGALITALLEEKPLPEAIRFAHAAAAIAVTRKGAQPSVPWREE
IDAFLDRQR

# Drug_Target_11_Reaction:
ATP + D-ribose = ADP + D-ribose 5-phosphate

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
ATP + D-ribose = ADP + D-ribose 5-phosphate

# Drug_Target_11_SwissProt_ID:
P0A9J6

# Drug_Target_11_SwissProt_Name:
RBSK_ECOLI

# Drug_Target_11_Synonyms:
EC 2.7.1.15

# Drug_Target_11_Theoretical_pI:
4.73

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Not Available

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
Not Available

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
AE008890

# Drug_Target_12_GenBank_ID_Protein:
Not Available

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
STM4066

# Drug_Target_12_Gene_Sequence:
>960 bp
ATGAAGGCCATGAATAAGGTTTGGGTTATCGGCGATGCCTCCGTTGATCTGGTGCCGGAA
AAACAGAACAGCTATCTGAAATGCCCCGGCGGAGCGTCGGCGAACGTGGGGGTATGCGTT
GCCAGGCTGGGCGGAGAGTGCGGTTTTATTGGCTGTCTTGGTGACGATGACGCCGGCCGC
TTCCTGCGCCAGGTTTTTCAGGATAACGGCGTGGATGTCACGTTTCTAAGGCTGGATGCG
GACCTGACCAGCGCGGTGCTGATCGTCAACCTGACGGCTGATGGGGAGCGCAGCTTTACC
TATCTGGTGCATCCGGGGGCTGATACCTACGTTTCGCCGCAGGACCTGCCGCCGTTCAGG
CAGTACGAATGGTTTTACTTCAGCTCAATTGGCCTCACCGACAGGCCCGCTCGCGAGGCG
TGCCTTGAGGGAGCGAGACGCATGCGAGAAGCCGGTGGCTACGTGTTATTCGACGTCAAC
TTACGCAGCAAAATGTGGGGGAATACTGATGAAATCCCTGAACTGATCGCCCGGTCCGCC
GCACTGGCTTCTATCTGCAAAGTCTCGGCAGATGAGCTGTGCCAGCTCAGCGGGGCCAGT
CACTGGCAGGATGCGCGTTATTACCTGCGCGATCTTGGGTGTGACACCACGATCATTTCG
CTGGGGGCCGATGGCGCGCTGTTGATTACCGCCGAGGGGGAGTTCCATTTTCCCGCACCA
CGCGTCGATGTTGTCGATACCACGGGAGCCGGTGATGCTTTTGTCGGCGGACTGTTGTTC
ACCCTTTCCCGCGCAAATTGCTGGGATCATGCCCTGCTGGCGGAAGCCATCAGCAATGCC
AATGCCTGCGGCGCTATGGCGGTGACGGCAAAAGGCGCAATGACCGCTTTACCGTTTCCT
GACCAACTCAACACTTTTCTTTCCAGCCATTCGCTGGCACAAGCCATGACCGTGAAATAA

# Drug_Target_12_General_Function:
Involved in ribokinase activity

# Drug_Target_12_General_References:
11677609	McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK: Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature. 2001 Oct 25;413(6858):852-6.

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
5466

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
34238

# Drug_Target_12_Name:
Putative sugar kinase

# Drug_Target_12_Number_of_Residues:
319

# Drug_Target_12_PDB_ID:
1TZ6

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00294	PfkB

# Drug_Target_12_Protein_Sequence:
>Putative sugar kinase
MKAMNKVWVIGDASVDLVPEKQNSYLKCPGGASANVGVCVARLGGECGFIGCLGDDDAGR
FLRQVFQDNGVDVTFLRLDADLTSAVLIVNLTADGERSFTYLVHPGADTYVSPQDLPPFR
QYEWFYFSSIGLTDRPAREACLEGARRMREAGGYVLFDVNLRSKMWGNTDEIPELIARSA
ALASICKVSADELCQLSGASHWQDARYYLRDLGCDTTIISLGADGALLITAEGEFHFPAP
RVDVVDTTGAGDAFVGGLLFTLSRANCWDHALLAEAISNANACGAMAVTAKGAMTALPFP
DQLNTFLSSHSLAQAMTVK

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Not Available

# Drug_Target_12_SwissProt_ID:
Q8ZKR2

# Drug_Target_12_SwissProt_Name:
Q8ZKR2_SALTY

# Drug_Target_12_Synonyms:
EC 2.7.1.4
EC 3.6.1.26

# Drug_Target_12_Theoretical_pI:
4.55

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
Not Available

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
Not Available

# Drug_Target_13_GenBank_ID_Gene:
AE000512

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
buk2

# Drug_Target_13_Gene_Sequence:
>1128 bp
GTGTTCAGAATCCTCACCATAAATCCCGGTTCTACATCCACAAAGCTGTCCATATTCGAA
GACGAAAGAATGGTGAAGATGCAAAATTTCAGTCATTCACCGGATGAACTCGGCAGATTC
CAGAAAATCCTGGATCAGCTTGAATTCAGGGAAAAGATAGCGAGACAGTTCGTCGAAGAA
ACTGGATACAGTCTGAGTTCTTTTTCCGCTTTTGTCAGCCGAGGAGGACTCCTCGATCCC
ATACCCGGGGGAGTGTATCTGGTGGACGGCCTAATGATAAAAACCCTGAAATCAGGAAAA
AACGGAGAACACGCTTCGAATCTGGGAGCGATCATAGCCCACAGATTCTCGTCTGAAACG
GGTGTTCCAGCCTACGTGGTGGATCCCGTCGTTGTCGATGAAATGGAAGATGTTGCACGT
GTCAGCGGACATCCAAACTATCAGAGAAAATCTATATTTCACGCTTTGAACCAGAAGACC
GTTGCAAAAGAAGTTGCCAGGATGATGAATAAAAGATACGAAGAGATGAACCTCGTTGTG
GCTCACATGGGTGGGGGCATATCAATCGCCGCACACAGAAAGGGAAGAGTGATCGACGTG
AACAACGCTCTGGACGGGGACGGACCGTTCACACCTGAAAGAAGCGGAACGCTACCTCTG
ACACAGCTTGTTGACCTTTGTTTCAGCGGGAAATTCACTTACGAAGAGATGAAGAAACGT
ATCGTGGGAAACGGTGGACTCGTGGCGTATCTTGGAACCAGCGATGCCAGAGAGGTGGTC
AGAAGAATCAAACAGGGTGATGAGTGGGCGAAGAGGGTTTACAGAGCGATGGCCTATCAG
ATAGCCAAGTGGATAGGTAAGATGGCAGCCGTTTTGAAAGGTGAGGTTGATTTCATAGTT
CTCACAGGTGGTCTGGCTCATGAAAAAGAGTTTCTGGTTCCATGGATCACCAAAAGGGTG
AGTTTCATAGCACCGGTACTTGTCTTTCCAGGAAGCAACGAGGAAAAAGCACTTGCCCTT
TCGGCACTGCGGGTGCTGAGAGGTGAAGAAAAGCCAAAAAATTATTCTGAAGAATCTCGA
AGGTGGAGAGAAAGGTATGATTCGTATCTTGATGGGATCTTACGGTAG

# Drug_Target_13_General_Function:
Involved in kinase activity

# Drug_Target_13_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.

# Drug_Target_13_HGNC_ID:
Not Available

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
4517

# Drug_Target_13_Locus:
Not Available

# Drug_Target_13_Molecular_Weight:
42023

# Drug_Target_13_Name:
Probable butyrate kinase 2

# Drug_Target_13_Number_of_Residues:
375

# Drug_Target_13_PDB_ID:
1SAZ

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00871	Acetate_kinase

# Drug_Target_13_Protein_Sequence:
>Probable butyrate kinase 2
MFRILTINPGSTSTKLSIFEDERMVKMQNFSHSPDELGRFQKILDQLEFREKIARQFVEE
TGYSLSSFSAFVSRGGLLDPIPGGVYLVDGLMIKTLKSGKNGEHASNLGAIIAHRFSSET
GVPAYVVDPVVVDEMEDVARVSGHPNYQRKSIFHALNQKTVAKEVARMMNKRYEEMNLVV
AHMGGGISIAAHRKGRVIDVNNALDGDGPFTPERSGTLPLTQLVDLCFSGKFTYEEMKKR
IVGNGGLVAYLGTSDAREVVRRIKQGDEWAKRVYRAMAYQIAKWIGKMAAVLKGEVDFIV
LTGGLAHEKEFLVPWITKRVSFIAPVLVFPGSNEEKALALSALRVLRGEEKPKNYSEESR
RWRERYDSYLDGILR

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
ATP + butanoate = ADP + butanoyl phosphate

# Drug_Target_13_SwissProt_ID:
Q9X278

# Drug_Target_13_SwissProt_Name:
BUK2_THEMA

# Drug_Target_13_Synonyms:
BK 2
Branched-chain carboxylic acid kinase 2
EC 2.7.2.7

# Drug_Target_13_Theoretical_pI:
9.68

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Not Available

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
Not Available

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
KIF1A

# Drug_Target_14_GenBank_ID_Gene:
X90840

# Drug_Target_14_GenBank_ID_Protein:
Not Available

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
KIF1A

# Drug_Target_14_Gene_Sequence:
>5073 bp
ATGGCCGGGGCTTCGGTGAAGGTGGCGGTGCGGGTCCGCCCCTTCAATTCCCGGGAAATG
AGCCGTGACTCCAAGTGCATCATTCAGATGTCTGGAAGCACCACCACCATTGTTAACCCC
AAACAGCCCAAGGAGACGCCCAAAAGCTTCAGCTTTGACTACTCCTACTGGTCGCACACC
TCACCTGAGGACATCAACTACGCGTCGCAGAAGCAGGTGTACCGGGACATCGGCGAGGAG
ATGCTGCAGCATGCCTTTGAGGGATACAACGTGTGCATCTTCGCCTATGGGCAGACGGGT
GCCGGCAAGTCCTACACCATGATGGGCAAGCAGGAGAAGGACCAGCAGGGCATCATCCCA
CAGCTCTGCGAGGACCTCTTCTCTCGGATCAACGACACGACCAACGACAACATGTCCTAC
TCCGTGGAGGTCAGCTACATGGAGATTTACTGTGAGCGCGTCCGTGACCTCCTGAACCCC
AAGAACAAGGGCAACCTTCGCGTGAGGGAGCACCCACTGCTGGGGCCCTACGTGGAGGAC
CTCTCCAAGCTGGCTGTCACCTCCTACAATGACATCCAGGACCTCATGGACTCAGGGAAC
AAGGCCAGGACCGTGGCGGCCACCAACATGAATGAGACCAGCAGTCGCTCCCACGCCGTC
TTCAACATCATCTTCACCCAGAAGCGCCATGACGCAGAGACCAATATCACCACGGAGAAG
GTGAGCAAAATCAGCCTGGTGGACCTGGCTGGGAGCGAGCGGGCTGACTCCACGGGAGCC
AAGGGCACGCGCCTCAAGGAGGGGGCCAACATCAACAAGTCGCTGACCACCCTGGGCAAG
GTCATCTCCGCCCTGGCTGAAATGGACTCCGGACCCAACAAGAACAAGAAAAAGAAGAAG
ACAGATTTCATTCCGTACCGAGATTCCGTGTTGACCTGGCTCCTCCGGGAAAACCTGGGC
GGTAACTCAAGGACAGCTATGGTGGCAGCCCTGAGTCCTGCAGACATCAACTACGATGAG
ACCCTTAGCACGCTGAGGTATGCTGACCGGGCCAAGCAGATCCGCTGCAATGCTGTCATC
AATGAGGACCCCAACAACAAGCTGATCCGCGAGCTGAAGGATGAGGTGACCCGGCTGCGG
GACCTTCTGTACGCCCAGGGTCTTGGCGACATCACTGACATGACCAATGCCCTGGTGGGT
ATGAGCCCCTCATCCTCGCTCTCAGCCCTGTCCAGCCGCGCGGCCTCCGTGTCCAGCCTC
CACGAGCGCATCTTGTTTGCCCCGGGCAGCGAGGAGGCCATTGAAAGACTGAAGGAAACA
GAGAAGATCATAGCTGAGCTCAATGAGACCTGGGAGGAGAAGCTGCGGCGGACAGAAGCC
ATCCGGATGGAGAGGGAAGCCCTGCTGGCCGAGATGGGTGTGGCCATGAGGGAGGATGGC
GGCACCTTGGGCGTATTCTCTCCCAAAAAGACACCACACCTCGTCAACCTGAACGAGGAC
CCGCTGATGTCTGAGTGCCTGCTCTACTACATCAAGGATGGGATCACCAGAGTGGGCAGG
GAGGATGGCGAGAGGCGGCAGGACATTGTTCTGAGTGGGCACTTCATCAAGGAGGAGCAC
TGCGTCTTCCGGAGCGACTCCAGGGGAGGCAGCGAAGCTGTGGTGACCTTGGAGCCCTGT
GAGGGGGCAGACACCTACGTCAATGGCAAGAAAGTCACAGAGCCCAGCATCCTGCGTTCA
GGAAACCGCATCATCATGGGTAAGAGCCATGTGTTCCGGTTCACCCACCCCGAGCAGGCC
CGGCAGGAGCGTGAGCGCACGCCTTGTGCGGAGACGCCAGCTGAGCCTGTGGACTGGGCC
TTCGCCCAGCGTGAGCTGCTGGAGAAGCAGGGCATCGACATGAAGCAGGAGATGGAGCAG
AGGCTCCAGGAACTGGAGGACCAGTACCGCCGCGAGCGGGAGGAGGCCACCTACCTGCTG
GAGCAGCAGCGGCTGGACTATGAGAGCAAGCTGGAGGCTCTGCAGAAGCAGATGGACTCC
AGGTACTACCCGGAGGTGAACGAGGAGGAGGAGGAGCCCGAGGATGAAGTCCAGTGGACA
GAGCGGGAGTGTGAGCTGGCGCTCTGGGCCTTCCGGAAGTGGAAGTGGTACCAGTTCACG
TCTCTGCGGGACCTGCTGTGGGGCAACGCCATCTTCCTCAAGGAGGCCAATGCCATCAGC
GTGGAGCTGAAAAAGAAGGTACAATTCCAGTTTGTCCTCCTGACGGACACACTCTACTCC
CCTCTGCCACCCGACCTGCTGCCCCCAGAGGCCGCCAAAGACCGAGAGAAGCGGCCCTTC
CCCCGCACCATTGTGGCCGTGGAGGTCCAGGACCAGAAGAACGGGGCCACCCACTACTGG
ACGCTGGAGAAGCTCAGGCAGCGTCTGGACCTGATGCGGGAGATGTACGACCGCGCTGCA
GAGGTGCCCTCCAGTGTCATCGAGGACTGTGACAACGTGGTGACCGGCGGAGACCCCTTC
TATGACCGCTTCCCCTGGTTCCGGCTGGTGGGCAGGGCCTTCGTGTACCTGAGCAACCTG
CTGTACCCCGTTCCCCTGGTACACCGTGTGGCAATCGTCAGCGAGAAGGGCGAGGTGAAG
GGCTTCCTCCGCGTGGCCGTCCAGGCCATCTCAGCCGATGAAGAGGCCCCTGATTATGGC
TCTGGCGTCCGCCAGTCGGGAACTGCTAAAATCTCCTTTGATGACCAGCATTTTGAAAAG
TTCCAGTCCGAGTCTTGCCCCGTGGTGGGGATGTCCCGCTCGGGAACCTCCCAGGAAGAG
CTTCGCATCGTGGAGGGCCAGGGCCAGGGTGCAGACGTGGGGCCCTCAGCCGATGAAGTC
AACAACAACACCTGTTCAGCAGTGCCCCCAGAAGGCCTCCTCCTAGACAGCTCTGAGAAA
GCCGCCCTGGATGGGCCCCTGGATGCTGCCCTGGACCACCTCCGCCTGGGCAACACCTTC
ACCTTCCGTGTGACAGTCCTGCAGGCGTCCAGCATCTCTGCCGAATATGCCGACATCTTC
TGCCAGTTCAACTTCATCCACCGCCACGACGAGGCCTTCTCCACAGAGCCCCTGAAGAAC
ACAGGCAGAGGCCCCCCACTTGGCTTCTACCACGTCCAGAACATCGCAGTGGAGGTGACC
AAGTCCTTCATTGAGTACATCAAGAGCCAGCCCATTGTTTTCGAGGTCTTTGGCCACTAC
CAGCAGCACCCGTTCCCGCCCCTCTGCAAGGACGTGCTCAGCCCCCTGAGGCCCTCGCGC
CGCCACTTCCCTCGGGTCATGCCACTGTCCAAGCCAGTGCCCGCCACCAAGCTCAGCACA
CTGACGCGGCCCTGTCCGGGACCCTGCCACTGCAAGTACGACCTGCTGGTCTACTTCGAG
ATCTGTGAGCTGGAGGCCAACGGCGATTACATCCCGGCCGTGGTGGACCACCGTGGGGGC
ATGCCATGCATGGGGACCTTCCTCCTCCACCAGGGCATCCAGCGACGGATTACGGTGACA
CTACTGCATGAGACAGGCAGCCATATCCGCTGGAAGGAAGTGCGCGAGCTGGTCGTGGGC
CGCATCCGAAACACTCCAGAGACCGACGAGTCCCTGATCGACCCCAACATCTTGTCTCTC
AACATCCTCTCTGCCGGATACATCCACCCAGCCCATGATGACCGGACCTTTTACCAATTT
GAGGCTGCGTGGAACAGCTCCATGCACAACTCTCTCCTGCTGAACCGGATCACCCCTTAT
CGAGAGAAAATCTACATGACACTCTCCGCTTATATCGAGATGGAGAACTGCACCCAGCCG
GCTGTTGTCACCAAGGACTTCTGCATGGTCTTCTATTCCCGTGATGCCAAGCTGCCAGCC
TCGCGCTCCATCCGCAACCTCTTTGGCAGTGGGAGCCTTCGGGCCTCAGAGAGTAACCGT
GTGACTGGTGTGTACGAGCTCAGCCTGTGCCACGTGGCTGACGCGGGCAGCCCAGGGATG
CAGCGCCGGCGCCGACGAGTCCTGGACACATCTGTGGCCTATGTCCGGGGCGAGGAGAAC
CTGGCAGGCTGGAGGCCCCGGAGTGACAGTCTCATTCTGGACCACCAGTGGGAGCTGGAG
AAGCTGAGCCTCCTGCAGGAGGTGGAGAAGACTAGGCACTACCTGCTCCTGCGGGAGAAG
CTGGAGACCGCCCAGCGGCCTGTCCCGGAGGCACTGTCCCCGGCCTTCAGCGAGGACTCT
GAGTCCCATGGCTCCTCCAGCGCCTCCTCCCCGCTCTCGGCTGAGGGCCGCCCATCACCC
CTGGAGGCTCCCAACGAGAGGCAGCGGGAGCTGGCCGTCAAGTGCTTGCGCCTGCTCACG
CACACATTCAACAGAGAGTACACACACAGCCACGTCTGCGTCAGTGCCAGCGAGAGCAAG
CTCTCCGAGATGTCTGTCACCCTGCTCCGGGACCCGTCGATGTCCCCTCTAGGGGTGGCC
ACTCTCACCCCCTCCTCCACTTGCCCCTCTCTGGTTGAAGGGCGGTACGGTGCCACTGAC
CTGAGGACCCCGCAGCCCTGCTCCCGGCCAGCCAGCCCAGAGCCCGAGCTGCTGCCAGAG
GCCGACTCCAAGAAGCTCCCTTCCCCTGCCCGGGCAACAGAGACAGACAAGGAGCCCCAG
CGCCTGCTGGTCCCTGACATCCAGGAGATCCGAGTCAGCCCGATCGTTTCCAAGAAGGGG
TACCTGCACTTCCTGGAGCCGCACACGTCAGGCTGGGCCAGGCGCTTCGTGGTGGTGCGG
CGCCCCTATGCCTACATGTACAACAGCGACAAGGACACCGTGGAGCGGTTCGTGCTCAAC
CTGGCCACTGCCCAGGTGGAGTACAGTGAGGACCAGCAGGCTATGCTCAAGACACCCAAC
ACATTCGCGGTGTGCACGGAACACCGCGGCATCCTGCTGCAGGCCGCCAGCGACAAGGAC
ATGCATGACTGGCTGTACGCCTTCAACCCCCTCCTGGCCGGGACCATACGGTCCAAGCTC
TCCAGAAGGAGGTCTGCCCAGATGCGGGTCTGA

# Drug_Target_14_General_Function:
Involved in microtubule motor activity

# Drug_Target_14_General_References:
8661001	Furlong RA, Zhou CY, Ferguson-Smith MA, Affara NA: Characterization of a kinesin-related gene ATSV, within the tuberous sclerosis locus (TSC1) candidate region on chromosome 9Q34. Genomics. 1996 May 1;33(3):421-9.

# Drug_Target_14_HGNC_ID:
HGNC:888

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
5312

# Drug_Target_14_Locus:
2q37.3

# Drug_Target_14_Molecular_Weight:
191066

# Drug_Target_14_Name:
Kinesin-like protein KIF1A

# Drug_Target_14_Number_of_Residues:
1690

# Drug_Target_14_PDB_ID:
1I6I

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00169	PH
PF00225	Kinesin
PF00498	FHA

# Drug_Target_14_Protein_Sequence:
>Kinesin-like protein KIF1A
MAGASVKVAVRVRPFNSREMSRDSKCIIQMSGSTTTIVNPKQPKETPKSFSFDYSYWSHT
SPEDINYASQKQVYRDIGEEMLQHAFEGYNVCIFAYGQTGAGKSYTMMGKQEKDQQGIIP
QLCEDLFSRINDTTNDNMSYSVEVSYMEIYCERVRDLLNPKNKGNLRVREHPLLGPYVED
LSKLAVTSYNDIQDLMDSGNKARTVAATNMNETSSRSHAVFNIIFTQKRHDAETNITTEK
VSKISLVDLAGSERADSTGAKGTRLKEGANINKSLTTLGKVISALAEMDSGPNKNKKKKK
TDFIPYRDSVLTWLLRENLGGNSRTAMVAALSPADINYDETLSTLRYADRAKQIRCNAVI
NEDPNNKLIRELKDEVTRLRDLLYAQGLGDITDMTNALVGMSPSSSLSALSSRAASVSSL
HERILFAPGSEEAIERLKETEKIIAELNETWEEKLRRTEAIRMEREALLAEMGVAMREDG
GTLGVFSPKKTPHLVNLNEDPLMSECLLYYIKDGITRVGREDGERRQDIVLSGHFIKEEH
CVFRSDSRGGSEAVVTLEPCEGADTYVNGKKVTEPSILRSGNRIIMGKSHVFRFNHPEQA
RQERERTPCAETPAEPVDWAFAQRELLEKQGIDMKQEMEQRLQELEDQYRREREEATYLL
EQQRLDYESKLEALQKQMDSRYYPEVNEEEEEPEDEVQWTERECELALWAFRKWKWYQFT
SLRDLLWGNAIFLKEANAISVELKKKVQFQFVLLTDTLYSPLPPDLLPPEAAKDRETRPF
PRTIVAVEVQDQKNGATHYWTLEKLRQRLDLMREMYDRAAEVPSSVIEDCDNVVTGGDPF
YDRFPWFRLVGRAFVYLSNLLYPVPLVHRVAIVSEKGEVKGFLRVAVQAISADEEAPDYG
SGVRQSGTAKISFDDQHFEKFQSESCPVVGMSRSGTSQEELRIVEGQGQGADVGPSADEV
NNNTCSAVPPEGLLLDSSEKAALDGPLDAALDHLRLGNTFTFRVTVLQASSISAEYADIF
CQFNFIHRHDEAFSTEPLKNTGRGPPLGFYHVQNIAVEVTKSFIEYIKSQPIVFEVFGHY
QQHPFPPLCKDVLSPLRPSRRHFPRVMPLSKPVPATKLSTLTRPCPGPCHCKYDLLVYFE
ICELEANGDYIPAVVDHRGGMPCMGTFLLHQGIQRRITVTLLHETGSHIRWKEVRELVVG
RIRNTPETDESLIDPNILSLNILSSGYIHPAQDDRTFYQFEAAWDSSMHNSLLLNRVTPY
REKIYMTLSAYIEMENCTQPAVVTKDFCMVFYSRDAKLPASRSIRNLFGSGSLRASESNR
VTGVYELSLCHVADAGSPGMQRRRRRVLDTSVAYVRGEENLAGWRPRSDSLILDHQWELE
KLSLLQEVEKTRHYLLLREKLETAQRPVPEALSPAFSEDSESHGSSSASSPLSAEGRPSP
LEAPNERQRELAVKCLRLLTHTFNREYTHSHVCVSASESKLSEMSVTLLRDPSMSPLGVA
TLTPSSTCPSLVEGRYGATDLRTPQPCSRPASPEPELLPEADSKKLPSPARATETDKEPQ
RLLVPDIQEIRVSPIVSKKGYLHFLEPHTSGWARRFVVVRRPYAYMYNSDKDTVERFVLN
LATAQVEYSEDQQAMLKTPNTFAVCTEHRGILLQAASDKDMHDWLYAFNPLLAGTIRSKL
SRRRSAQMRV

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Motor for anterograde axonal transport of synaptic vesicle precursors (By similarity)

# Drug_Target_14_SwissProt_ID:
Q12756

# Drug_Target_14_SwissProt_Name:
KIF1A_HUMAN

# Drug_Target_14_Synonyms:
Axonal transporter of synaptic vesicles
Microtubule-based motor KIF1A
UNC-104-and KIF1A-related protein
hUNC-104

# Drug_Target_14_Theoretical_pI:
6.13

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
J05221

# Drug_Target_1_GenBank_ID_Protein:
149542

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
fgs

# Drug_Target_1_Gene_Sequence:
>1287 bp
ATGAATTACACAGAAACGGTTGCCTACATTCATTCTTTTCCGCGTTTGGCCAAGACCGGT
GACCATCGGCGGATTTTAACGTTATTACATGCACTCGGCAATCCGCAGCAACAAGGGCGG
TATATTCACGTGACTGGTACTAATGGAAAAGGCTCAGCCGCTAATGCGATTGCACATGTC
CTTGAGGCAAGCGGTTTGACAGTCGGGTTATATACCTCGCCGTTTATCATGCGGTTTAAT
GAACGGATCATGATTGACCATGAACCGATTCCGGATGCTGCGTTAGTCAATGCGGTTGCG
TTTGTCAGGGCTGCACTGGAGCGGCTTCAGCAGCAACAAGCTGATTTTAACGTGACGGAA
TTTGAATTCATTACCGCGCTGGGCTATTGGTATTTTCGTCAGCGTCAGGTTGATGTTGCG
GTGATTGAAGTCGGTATTGGCGGCGACACGGATTCGACCAATGTCATCACGCCGGTTGTC
AGTGTTTTGACCGAGGTTGCTTTAGATCACCAGAAGTTGCTGGGGCATACGATTACGGCG
ATTGCCAAGCATAAGGCCGGTATTATCAAACGGGGTATTCCGGTTGTAACCGGTAACTTG
GTGCCGGATGCTGCTGCCGTTGTCGCAGCCAAGGTCGCGACAACAGGGAGTCAATGGTTG
CGTTTTGACCGCGATTTTTCGGTTCCTAAGGCTAAGCTTCACGGTTGGGGCCAACGGTTT
ACTTATGAAGACCAAGATGGACGTATTAGTGATTTGGAGGTGCCGTTGGTTGGCGATTAC
CAGCAACGTAATATGGCAATTGCGATTCAAACGGCAAAAGTGTATGCCAAGCAGACAGAA
TGGCCTTTGACGCCCCAGAATATTCGCCAAGGGCTTGCTGCCAGTCATTGGCCAGCCCGA
CTCGAAAAGATAAGTGATACGCCTTTGATCGTCATTGACGGGGCGCACAATCCGGATGGC
ATCAATGGTTTGATTACGGCGCTAAAGCAACTTTTTTCCCAACCCATTACTGTTATTGCC
GGCATCTTGGCGGATAAAGACTATGCGGCGATGGCGGATAGGCTGACCGCGGCATTTTCC
ACGGTTTATCTGGTTCCGGTGCCGGGGACGCCGCGCGCCTTGCCTGAGGCTGGTTATGAG
GCGCTGCACGAAGGTCGGTTAAAGGATTCGTGGCAGGAAGCATTGGCGGCGAGTCTTAAT
GATGTGCCGGATCAGCCGATTGTGATCACCGGTTCGCTGTATTTAGCCTCAGCTGTTCGT
CAAACTTTATTAGGGGGAAAATCATGA

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
2105929	Toy J, Bognar AL: Cloning and expression of the gene encoding Lactobacillus casei folylpoly-gamma-glutamate synthetase in Escherichia coli and determination of its primary structure. J Biol Chem. 1990 Feb 15;265(5):2492-9.
9618466	Sun X, Bognar AL, Baker EN, Smith CA: Structural homologies with ATP- and folate-binding enzymes in the crystal structure of folylpolyglutamate synthetase. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6647-52.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2717

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
46590

# Drug_Target_1_Name:
Folylpolyglutamate synthase

# Drug_Target_1_Number_of_Residues:
428

# Drug_Target_1_PDB_ID:
1FGS

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02875	Mur_ligase_C
PF08245	Mur_ligase_M

# Drug_Target_1_Protein_Sequence:
>Folylpolyglutamate synthase
MNYTETVAYIHSFPRLAKTGDHRRILTLLHALGNPQQQGRYIHVTGTNGKGSAANAIAHV
LEASGLTVGLYTSPFIMRFNERIMIDHEPIPDAALVNAVAFVRAALERLQQQQADFNVTE
FEFITALGYWYFRQRQVDVAVIEVGIGGDTDSTNVITPVVSVLTEVALDHQKLLGHTITA
IAKHKAGIIKRGIPVVTGNLVPDAAAVVAAKVATTGSQWLRFDRDFSVPKAKLHGWGQRF
TYEDQDGRISDLEVPLVGDYQQRNMAIAIQTAKVYAKQTEWPLTPQNIRQGLAASHWPAR
LEKISDTPLIVIDGAHNPDGINGLITALKQLFSQPITVIAGILADKDYAAMADRLTAAFS
TVYLVPVPGTPRALPEAGYEALHEGRLKDSWQEALAASLNDVPDQPIVITGSLYLASAVR
QTLLGGKS

# Drug_Target_1_Reaction:
ATP + tetrahydropteroyl-[gamma-Glu]n + L-glutamate = ADP + phosphate + tetrahydropteroyl-[gamma-Glu]n+1

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Conversion of folates to polyglutamate derivatives. It preferes 5,10-methylenetetrahydrofolate, rather than 10- formyltetrahydrofolate as folate substrate

# Drug_Target_1_SwissProt_ID:
P15925

# Drug_Target_1_SwissProt_Name:
FOLC_LACCA

# Drug_Target_1_Synonyms:
EC 6.3.2.17
FPGS
Folylpoly-gamma-glutamate synthetase
Tetrahydrofolate synthase
Tetrahydrofolylpolyglutamate synthase

# Drug_Target_1_Theoretical_pI:
7.02

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
U30501

# Drug_Target_2_GenBank_ID_Protein:
940146

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
cheA

# Drug_Target_2_Gene_Sequence:
>2016 bp
ATGATGGAAGAATATCTCGGAGTGTTTGTCGATGAGACAAAAGAATACCTTCAAAATCTG
AACGATACCCTCCTCGAATTGGAGAAAAATCCCGAAGATATGGAACTCATAAACGAAGCG
TTCAGGGCTCTTCATACCCTGAAAGGAATGGCAGGTACAATGGGGTTTTCCAGTATGGCG
AAGCTCTGCCATACCTTAGAAAACATCCTCGATAAAGCCAGAAACAGCGAGATAAAGATA
ACTTCCGATCTCCTCGATAAGATCTTCGCGGGGGTCGATATGATAACCAGAATGGTTGAT
AAGATCGTCTCCGAGGGAAGTGACGACATCGGAGAAAACATAGACGTGTTCTCCGACACC
ATAAAAAGCTTTGCATCATCGGGAAAAGAGAAGCCTTCAGAAATCAAAAATGAAACGGAA
ACAAAGGGTGAGGAAGAACACAAAGGAGAATCAACAAGCAATGAAGAAGTCGTAGTTCTT
CCTGAAGAAGTTGCCCACGTTCTTCAGGAAGCGAGAAACAAGGGTTTCAAAACGTTTTAT
ATTAAAGTGATTCTCAAAGAAGGAACGCAGTTGAAATCCGCCAGGATTTACCTCGTTTTC
CACAAGCTTGAAGAACTGAAGTGTGAAGTTGTGAGAACGATTCCTTCGGTTGAAGAGATA
GAAGAAGAGAAATTCGAAAACGAAGTGGAACTCTTCGTAATCTCCCCTGTGGATCTGGAG
AAACTCTCTGAAGCTCTGTCAAGCATCGCCGATATAGAGAGGGTAATAATAAAAGAAGTA
ACCGCCGTCACCGAAGAATCAGGGGCTGAGAAAAGAACCGAGAAAGAAGAGAAAACTGAA
AAAACTGAGGAAAAGGCCGAAAGAAAAAAGGTTATTTCGCAAACAGTCAGGGTAGATATA
GAGAAACTGGGCAATTTGATGGATTTGATGGGAGAACTGGTCATCGCAAGGAGCAGAATA
CTGGAAACGCTCAAGAAATACAACATAAAAGAACTGGATGAGAGTTTGTCTCATCTCAGC
AGGATCACCTTAGACCTTCAGAATGTTGTGATGAAGATCAGAATGGTTCCCATCTCCTTT
GTTTTCAACAGATTCCCTCGAATGGTGAGAGACCTTGCCAAAAAGATGAACAAAGAAGTG
AATTTCATCATGAGAGGAGAAGACACAGAGCTCGACAGAACGTTCGTTGAAGAAATTGGC
GAACCCCTGCTCCATCTCCTGAGAAACGCCATCGACCACGGTATAGAACCCAAAGAAGAA
CGAATAGCCAAAGGAAAACCCCCCATTGGAACACTCATTCTCTCGGCACGTCACGAGGGA
AACAACGTGGTAATAGAAGTCGAAGATGACGGAAGGGGTATAGACAAGGAAAAGATCATC
AGAAAAGCCATAGAAAAGGGACTCATAGATGAATCAAAGGCCGCTACCCTTTCTGATCAG
GAGATTCTGAACTTCCTCTTCGTTCCGGGATTCTCCACAAAGGAAAAAGTCTCAGAAGTC
TCCGGAAGAGGCGTGGGAATGGATGTCGTGAAAAATGTGGTGGAATCTTTGAATGGTAGC
ATAAGCATAGAAAGCGAGAAAGATAAAGGAACAAAAGTTACGATAAGACTACCGCTCACT
CTGGCCATCATTCAGGCGCTCCTCGTCAAAGTCAACAATCTCGTCTACGCGATTCCGATA
GCGAACATAGACACAATACTCAGCATTTCAAAAGAGGATATTCAAAGAGTTCAGGACAGA
GATGTGATAGTCATAAGAGGAGAAGTGATACCCGTTTACCGTCTGTGGGAAGTGCTTCAA
ATAGAGCACAAAGAAGAACTGGAGGAGATGGAAGCGGTTATTGTGAGGGTAGGAAACAGG
AAGTACGGTATCGTCGTAGACGATCTTCTCGGTCAGGACGATATCGTGATAAAATCTCTT
GGAAAGGTGTTCTCTGAGGTGAAGGAATTCAGCGGAGCAGCTATTCTCGGTGATGGTAGT
ATAGCGCTGATAATCAACGTCTCCGGCATTGTATAA

# Drug_Target_2_General_Function:
Signal transduction mechanisms

# Drug_Target_2_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
8550470	Swanson RV, Sanna MG, Simon MI: Thermostable chemotaxis proteins from the hyperthermophilic bacterium Thermotoga maritima. J Bacteriol. 1996 Jan;178(2):484-9.
9989504	Bilwes AM, Alex LA, Crane BR, Simon MI: Structure of CheA, a signal-transducing histidine kinase. Cell. 1999 Jan 8;96(1):131-41.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2615

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
75557

# Drug_Target_2_Name:
Chemotaxis protein cheA

# Drug_Target_2_Number_of_Residues:
671

# Drug_Target_2_PDB_ID:
1B3Q

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01584	CheW
PF01627	Hpt
PF02518	HATPase_c
PF02895	H-kinase_dim
PF07194	P2

# Drug_Target_2_Protein_Sequence:
>Chemotaxis protein cheA
MMEEYLGVFVDETKEYLQNLNDTLLELEKNPEDMELINEAFRALHTLKGMAGTMGFSSMA
KLCHTLENILDKARNSEIKITSDLLDKIFAGVDMITRMVDKIVSEGSDDIGENIDVFSDT
IKSFASSGKEKPSEIKNETETKGEEEHKGESTSNEEVVVLPEEVAHVLQEARNKGFKTFY
IKVILKEGTQLKSARIYLVFHKLEELKCEVVRTIPSVEEIEEEKFENEVELFVISPVDLE
KLSEALSSIADIERVIIKEVTAVTEESGAEKRTEKEEKTEKTEEKAERKKVISQTVRVDI
EKLDNLMDLMGELVIARSRILETLKKYNIKELDESLSHLSRITLDLQNVVMKIRMVPISF
VFNRFPRMVRDLAKKMNKEVNFIMRGEDTELDRTFVEEIGEPLLHLLRNAIDHGIEPKEE
RIAKGKPPIGTLILSARHEGNNVVIEVEDDGRGIDKEKIIRKAIEKGLIDESKAATLSDQ
EILNFLFVPGFSTKEKVSEVSGRGVGMDVVKNVVESLNGSISIESEKDKGTKVTIRLPLT
LAIIQALLVKVNNLVYAIPIANIDTILSISKEDIQRVQDRDVIVIRGEVIPVYRLWEVLQ
IEHKEELEEMEAVIVRVGNRKYGIVVDDLLGQDDIVIKSLGKVFSEVKEFSGAAILGDGS
IALIINVSGIV

# Drug_Target_2_Reaction:
ATP + protein L-histidine = ADP + protein N-phospho-L-histidine

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Involved in the transmission of sensory signals from the chemoreceptors to the flagellar motors. CheA is autophosphorylated; it can transfer its phosphate group to either cheB or cheY

# Drug_Target_2_SwissProt_ID:
Q56310

# Drug_Target_2_SwissProt_Name:
CHEA_THEMA

# Drug_Target_2_Synonyms:
EC 2.7.13.3

# Drug_Target_2_Theoretical_pI:
4.64

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
L42023

# Drug_Target_3_GenBank_ID_Protein:
1574695

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
murC

# Drug_Target_3_Gene_Sequence:
>1428 bp
ATGAAACATTCCCACGAAGAAATTAGAAAAATTATCCCTGAAATGCGCCGTGTACAGCAA
ATTCATTTCATTGGCATTGGTGGTGCGGGAATGAGCGGCATTGCAGAAATTTTATTAAAT
GAAGGTTATCAAATTTCAGGTTCAGATATTGCCGATGGCGTAGTCACTCAACGTTTAGCT
CAAGCTGGGGCAAAAATCTACATTGGTCATGCAGAAGAACATATTGAAGGTGCCAGTGTT
GTTGTTGTGTCTAGTGCGATAAAAGATGATAACCCTGAATTAGTTACATCGAAACAAAAA
CGCATTCCAGTGATTCAACGCGCACAAATGTTGGCGGAGATTATGCGTTTTCGTCACGGT
ATTGCTGTTGCAGGAACACACGGGAAAACGACAACAACAGCAATGATTTCAATGATTTAC
ACCCAAGCTAAACTTGATCCGACTTTTGTAAATGGCGGTTTAGTGAAATCGGCGGGTAAG
AATGCACATTTAGGAGCAAGTCGTTATTTAATTGCCGAAGCCGATGAAAGTGATGCGTCG
TTTTTGCATTTACAGCCAATGGTATCTGTTGTAACTAATATGGAGCCAGACCATATGGAT
ACTTACGAAGGCGATTTTGAAAAAATGAAAGCCACTTATGTGAAATTCCTGCATAATTTA
CCCTTCTATGGTTTAGCCGTGATGTGCGCTGATGATCCTGTTTTAATGGAACTTGTGCCA
AAAGTTGGTCGCCAAGTGATTACATATGGTTTTAGTGAACAGGCAGATTATCGCATTGAA
GATTATGAACAAACAGGTTTTCAAGGTCATTACACGGTGATTTGCCCAAATAATGAACGT
ATTAATGTGTTGCTCAATGTTCCTGGAAAACATAATGCATTAAATGCAACGGCTGCACTT
GCTGTAGCAAAAGAAGAGGGTATTGCTAACGAGGCAATTTTAGAAGCTCTGGCTGATTTT
CAGGGGGCTGGTCGTCGTTTTGATCAGCTAGGCGAATTTATTCGTCCAAATGGTAAAGTG
CGTTTAGTTGATGATTATGGTCATCATCCAACAGAAGTAGGCGTAACCATTAAAGCGGCG
CGAGAAGGCTGGGGAGATAAACGTATTGTAATGATTTTCCAACCGCATCGTTATTCTCGC
ACTCGTGATTTGTTTGATGATTTTGTACAAGTGCTTTCGCAAGTAGACGCTTTGATTATG
CTTGATGTGTACGCAGCGGGAGAAGCCCCTATTGTTGGCGCTGACAGTAAATCTCTTTGC
CGTTCCATTCGTAATCTTGGTAAAGTTGATCCTATTTTGGTATCAGATACTTCGCAACTA
GGCGATGTTCTCGATCAAATTATTCAAGATGGCGATTTGATTTTGGCACAAGGTGCTGGT
AGCGTAAGTAAAATTTCTCGTGGCTTGGCTGAATCTTGGAAGAATTAA

# Drug_Target_3_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_3_General_References:
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
2299

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
51995

# Drug_Target_3_Name:
UDP-N-acetylmuramate--L-alanine ligase

# Drug_Target_3_Number_of_Residues:
475

# Drug_Target_3_PDB_ID:
1GQY

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01225	Mur_ligase
PF02875	Mur_ligase_C
PF08245	Mur_ligase_M

# Drug_Target_3_Protein_Sequence:
>UDP-N-acetylmuramate--L-alanine ligase
MKHSHEEIRKIIPEMRRVQQIHFIGIGGAGMSGIAEILLNEGYQISGSDIADGVVTQRLA
QAGAKIYIGHAEEHIEGASVVVVSSAIKDDNPELVTSKQKRIPVIQRAQMLAEIMRFRHG
IAVAGTHGKTTTTAMISMIYTQAKLDPTFVNGGLVKSAGKNAHLGASRYLIAEADESDAS
FLHLQPMVSVVTNMEPDHMDTYEGDFEKMKATYVKFLHNLPFYGLAVMCADDPVLMELVP
KVGRQVITYGFSEQADYRIEDYEQTGFQGHYTVICPNNERINVLLNVPGKHNALNATAAL
AVAKEEGIANEAILEALADFQGAGRRFDQLGEFIRPNGKVRLVDDYGHHPTEVGVTIKAA
REGWGDKRIVMIFQPHRYSRTRDLFDDFVQVLSQVDALIMLDVYAAGEAPIVGADSKSLC
RSIRNLGKVDPILVSDTSQLGDVLDQIIQDGDLILAQGAGSVSKISRGLAESWKN

# Drug_Target_3_Reaction:
ATP + UDP-N-acetylmuramate + L-alanine = ADP + phosphate + UDP-N-acetylmuramoyl-L-alanine

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Cell wall formation

# Drug_Target_3_SwissProt_ID:
P45066

# Drug_Target_3_SwissProt_Name:
MURC_HAEIN

# Drug_Target_3_Synonyms:
EC 6.3.2.8
UDP-N- acetylmuramoyl-L-alanine synthetase

# Drug_Target_3_Theoretical_pI:
5.97

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
D84362

# Drug_Target_4_GenBank_ID_Protein:
1304070

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
gntK

# Drug_Target_4_Gene_Sequence:
>528 bp
TTGAGCACGACTAACCATGATCACCACATTTACGTCTTGATGGGCGTATCGGGCAGCGGC
AAATCTGCGGTCGCCAGTGAAGTGGCGCATCAACTTCATGCCGCGTTTCTTGATGGCGAT
TTCCTCCATCCACGGCGCAATATCGAAAAAATGGCGTCTGGCGAACCACTGAATGACGAC
GATCGCAAACCGTGGTTGCAGGCGCTGAACGACGCCGCGTTTGCTATGCAGCGCACTAAT
AAAGTGTCGCTGATCGTCTGTTCTGCATTGAAAAAACACTATCGCGACTTGCTGCGTGAA
GGTAATCCGAATCTCTCTTTCATCTATTTGAAAGGCGATTTTGATGTGATTGAAAGCCGC
CTGAAAGCGCGCAAAGGCCATTTCTTTAAAACCCAAATGTTGGTGACGCAGTTTGAAACG
CTGCAGGAGCCGGGTGCGGACGAAACCGATGTACTGGTGGTGGATATCGATCAACCGCTG
GAAGGTGTTGTGGCAAGCACCATTGAGGTTATTAAAAAAGGCAAATAA

# Drug_Target_4_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_4_General_References:
11468405	Kraft L, Sprenger GA, Lindqvist Y: Crystallization and preliminary X-ray crystallographic studies of recombinant thermoresistant gluconate kinase GntK from Escherichia coli. Acta Crystallogr D Biol Crystallogr. 2001 Aug;57(Pt 8):1159-61. Epub 2001 Jul 23.
8655507	Tong S, Porco A, Isturiz T, Conway T: Cloning and molecular genetic characterization of the Escherichia coli gntR, gntK, and gntU genes of GntI, the main system for gluconate metabolism. J Bacteriol. 1996 Jun;178(11):3260-9.
9135111	Izu H, Adachi O, Yamada M: Gene organization and transcriptional regulation of the gntRKU operon involved in gluconate uptake and catabolism of Escherichia coli. J Mol Biol. 1997 Apr 11;267(4):778-93.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
2621

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
19544

# Drug_Target_4_Name:
Thermoresistant gluconokinase

# Drug_Target_4_Number_of_Residues:
175

# Drug_Target_4_PDB_ID:
1KOF

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF01202	SKI

# Drug_Target_4_Protein_Sequence:
>Thermoresistant gluconokinase
MSTTNHDHHIYVLMGVSGSGKSAVASEVAHQLHAAFLDGDFLHPRRNIEKMASGEPLNDD
DRKPWLQALNDAAFAMQRTNKVSLIVCSALKKHYRDLLREGNPNLSFIYLKGDFDVIESR
LKARKGHFFKTQMLVTQFETLQEPGADETDVLVVDIDQPLEGVVASTIEVIKKGK

# Drug_Target_4_Reaction:
ATP + D-gluconate = ADP + 6-phospho-D-gluconate

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
ATP + D-gluconate = ADP + 6-phospho-D- gluconate

# Drug_Target_4_SwissProt_ID:
P46859

# Drug_Target_4_SwissProt_Name:
GNTK_ECOLI

# Drug_Target_4_Synonyms:
EC 2.7.1.12
Gluconate kinase 2

# Drug_Target_4_Theoretical_pI:
6.73

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
L20897

# Drug_Target_5_GenBank_ID_Protein:
304887

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
purT

# Drug_Target_5_Gene_Sequence:
>1179 bp
ATGACGTTATTAGGCACTGCGCTGCGTCCGGCAGCAACTCGCGTGATGTTATTAGGCTCC
GGTGAACTGGGTAAAGAAGTGGCAATCGAGTGTCAGCGTCTCGGCGTAGAGGTGATTGCC
GTCGATCGCTATGCCGACGCACCAGCCATGCATGTCGCGCATCGCTCCCATGTCATTAAT
ATGCTTGATGGTGATGCATTACGCCGTGTGGTTGAACTGGAAAAACCACATTATATCGTG
CCGGAGATCGAAGCTATTGCCACCGATATGCTGATCCAACTTGAAGAGGAAGGACTGAAT
GTTGTCCCCTGCGCTCGCGCAACGAAATTAACGATGAATCGCGAGGGTATCCGTCGCCTG
GCGGCAGAAGAGCTGCAGCTGCCCACTTCCACTTATCGTTTTGCCGATAGCGAAAGCCTT
TTCCGCGAGGCGGTTGCTGACATTGGCTATCCCTGCATTGTAAAACCGGTGATGAGCTCT
TCCGGCAAGGGGCAGACGTTTATTCGTTCTGCAGAGCAACTTGCTCAGGCATGGAAGTAC
GCTCAGCAAGGCGGTCGCGCCGGAGCGGGCCGCGTAATTGTTGAAGGCGTCGTTAAGTTT
GACTTCGAAATTACCCTGCTAACCGTCAGCGCGGTGGATGGCGTCCATTTCTGTGCACCA
GTAGGTCATCGCCAGGAAGATGGCGACTACCGTGAATCCTGGCAACCACAGCAAATGAGC
CCGCTTGCCCTTGAACGTGCGCAGGAGATTGCCCGTAAAGTGGTGCTGGCACTGGGCGGT
TATGGGTTGTTTGGTGTCGAGCTATTTGTCTGTGGTGATGAGGTGATTTTCAGTGAGGTC
TCCCCTCGTCCACATGATACCGGGATGGTGACGTTAATTTCTCAAGATCTCTCAGAGTTT
GCCCTGCATGTACGTGCCTTCCTCGGACTTCCGGTTGGCGGGATCCGTCAGTATGGTCCT
GCAGCTTCTGCCGTTATTCTGCCACAACTGACCAGTCAGAATGTCACGTTTGATAATGTG
CAGAATGCCGTAGGCGCAGATTTGCAGATTCGTTTATTTGGTAAGCCGGAAATTGATGGC
AGCCGTCGTCTGGGGGTGGCACTGGCTACTGCAGAGAGTGTTGTTGACGCCATTGAACGC
GCGAAGCACGCCGCCGGACAGGTAAAAGTACAGGGTTAA

# Drug_Target_5_General_Function:
Nucleotide transport and metabolism

# Drug_Target_5_General_References:
10913290	Thoden JB, Firestine S, Nixon A, Benkovic SJ, Holden HM: Molecular structure of Escherichia coli PurT-encoded glycinamide ribonucleotide transformylase. Biochemistry. 2000 Aug 1;39(30):8791-802.
8117714	Marolewski A, Smith JM, Benkovic SJ: Cloning and characterization of a new purine biosynthetic enzyme: a non-folate glycinamide ribonucleotide transformylase from E. coli. Biochemistry. 1994 Mar 8;33(9):2531-7.
9097040	Itoh T, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Kasai H, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Seki Y, Horiuchi T, et al.: A 460-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 40.1-50.0 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):379-92.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
2817

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
42434

# Drug_Target_5_Name:
Phosphoribosylglycinamide formyltransferase 2

# Drug_Target_5_Number_of_Residues:
392

# Drug_Target_5_PDB_ID:
1EZ1

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF02222	ATP-grasp

# Drug_Target_5_Protein_Sequence:
>Phosphoribosylglycinamide formyltransferase 2
MTLLGTALRPAATRVMLLGSGELGKEVAIECQRLGVEVIAVDRYADAPAMHVAHRSHVIN
MLDGDALRRVVELEKPHYIVPEIEAIATDMLIQLEEEGLNVVPCARATKLTMNREGIRRL
AAEELQLPTSTYRFADSESLFREAVADIGYPCIVKPVMSSSGKGQTFIRSAEQLAQAWKY
AQQGGRAGAGRVIVEGVVKFDFEITLLTVSAVDGVHFCAPVGHRQEDGDYRESWQPQQMS
PLALERAQEIARKVVLALGGYGLFGVELFVCGDEVIFSEVSPRPHDTGMVTLISQDLSEF
ALHVRAFLGLPVGGIRQYGPAASAVILPQLTSQNVTFDNVQNAVGADLQIRLFGKPEIDG
SRRLGVALATAESVVDAIERAKHAAGQVKVQG

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Catalyzes two reactions:the first one is the production of beta-formyl glycinamide ribonucleotide (GAR) from formate, ATP and beta GAR; the second, a side reaction, is the production of acetyl phosphate and ADP from acetate and ATP

# Drug_Target_5_SwissProt_ID:
P33221

# Drug_Target_5_SwissProt_Name:
PURT_ECOLI

# Drug_Target_5_Synonyms:
5'-phosphoribosylglycinamide transformylase 2
EC 2.1.2.-
Formate-dependent GAR transformylase
GAR transformylase 2
GART 2

# Drug_Target_5_Theoretical_pI:
5.46

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
INSR

# Drug_Target_6_GenBank_ID_Gene:
M10051

# Drug_Target_6_GenBank_ID_Protein:
307070

# Drug_Target_6_GeneCard_ID:
INSR

# Drug_Target_6_Gene_Name:
INSR

# Drug_Target_6_Gene_Sequence:
>4149 bp
ATGGGCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG
CTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC
CGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG
CAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA
CTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG
GACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG
GTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC
CGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG
TCCCGTATCCTGGATTCCGTGGAGGATAATCACATCGTGTTGAACAAAGATGACAACGAG
GAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC
ATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG
ACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG
GGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG
GACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT
GTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC
TGCCACCAATACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG
ATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC
CTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC
ACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG
CTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC
TACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG
GAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC
TGGAGCAAACACAACCTCACCACCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA
CTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG
AGAAACGACATTGCCCTGAAGACCAATGGGGACAAGGCATCCTGTGAAAATGAGTTACTT
AAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG
CCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG
AATGTGACGGAGTTCGATGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC
ATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG
CGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG
GATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC
AACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG
AAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG
AGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG
CCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT
GAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG
AAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT
TTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA
CGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC
CCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG
GTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC
GAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC
AGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA
ATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG
ATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC
TCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC
TACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC
TATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC
CCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA
AAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC
AGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA
GAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC
AATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC
GAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC
TTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG
GTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA
GAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG
GCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG
GCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG
ACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA
CGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG
TCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG
TCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC
TGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG
CCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG
GTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG
TTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG
GGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT
TACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT
CCTTCCTAA

# Drug_Target_6_General_Function:
Involved in transmembrane receptor protein tyrosine kinase activity

# Drug_Target_6_General_References:
10443650	Longo N, Wang Y, Pasquali M: Progressive decline in insulin levels in Rabson-Mendenhall syndrome. J Clin Endocrinol Metab. 1999 Aug;84(8):2623-9.
10733238	Rique S, Nogues C, Ibanez L, Marcos MV, Ferragut J, Carrascosa A, Potau N: Identification of three novel mutations in the insulin receptor gene in type A insulin resistant patients. Clin Genet. 2000 Jan;57(1):67-9.
11260230	Osawa H, Nishimiya T, Ochi M, Niiya T, Onuma H, Kitamuro F, Kaino Y, Kida K, Makino H: Identification of novel C253Y missense and Y864X nonsense mutations in the insulin receptor gene in type A insulin-resistant patients. Clin Genet. 2001 Mar;59(3):194-7.
11374898	Lin WH, Huang CJ, Liu MW, Chang HM, Chen YJ, Tai TY, Chuang LM: Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B. Genomics. 2001 May 15;74(1):12-20.
12023989	Longo N, Wang Y, Smith SA, Langley SD, DiMeglio LA, Giannella-Neto D: Genotype-phenotype correlation in inherited severe insulin resistance. Hum Mol Genet. 2002 Jun 1;11(12):1465-75.
12107746	Hamer I, Foti M, Emkey R, Cordier-Bussat M, Philippe J, De Meyts P, Maeder C, Kahn CR, Carpentier JL: An arginine to cysteine(252) mutation in insulin receptors from a patient with severe insulin resistance inhibits receptor internalisation but preserves signalling events. Diabetologia. 2002 May;45(5):657-67. Epub 2002 Apr 5.
12538626	George S, Johansen A, Soos MA, Mortensen H, Gammeltoft S, Saudek V, Siddle K, Hansen L, O'Rahilly S: Deletion of V335 from the L2 domain of the insulin receptor results in a conformationally abnormal receptor that is unable to bind insulin and causes Donohue's syndrome in a human subject. Endocrinology. 2003 Feb;144(2):631-7.
1321605	Dickens M, Tavare JM: Analysis of the order of autophosphorylation of human insulin receptor tyrosines 1158, 1162 and 1163. Biochem Biophys Res Commun. 1992 Jul 15;186(1):244-50.
1470163	Kasuga M, Kishimoto M, Hashiramoto M, Yonezawa K, Kazumi T, Hagino H, Shii K: [Insulin receptor Arg1131-->Gln: a novel mutation in the catalytic loop of insulin receptor observed in insulin resistant diabetes] Nippon Geka Gakkai Zasshi. 1992 Sep;93(9):968-71.
1472036	Schaffer L, Ljungqvist L: Identification of a disulfide bridge connecting the alpha-subunits of the extracellular domain of the insulin receptor. Biochem Biophys Res Commun. 1992 Dec 15;189(2):650-3.
1563582	Kim H, Kadowaki H, Sakura H, Odawara M, Momomura K, Takahashi Y, Miyazaki Y, Ohtani T, Akanuma Y, Yazaki Y, et al.: Detection of mutations in the insulin receptor gene in patients with insulin resistance by analysis of single-stranded conformational polymorphisms. Diabetologia. 1992 Mar;35(3):261-6.
1607067	Barbetti F, Gejman PV, Taylor SI, Raben N, Cama A, Bonora E, Pizzo P, Moghetti P, Muggeo M, Roth J: Detection of mutations in insulin receptor gene by denaturing gradient gel electrophoresis. Diabetes. 1992 Apr;41(4):408-15.
1607076	Cocozza S, Porcellini A, Riccardi G, Monticelli A, Condorelli G, Ferrara A, Pianese L, Miele C, Capaldo B, Beguinot F, et al.: NIDDM associated with mutation in tyrosine kinase domain of insulin receptor gene. Diabetes. 1992 Apr;41(4):521-6.
1730625	van der Vorm ER, van der Zon GC, Moller W, Krans HM, Lindhout D, Maassen JA: An Arg for Gly substitution at position 31 in the insulin receptor, linked to insulin resistance, inhibits receptor processing and transport. J Biol Chem. 1992 Jan 5;267(1):66-71.
1890161	Cama A, de la Luz Sierra M, Ottini L, Kadowaki T, Gorden P, Imperato-McGinley J, Taylor SI: A mutation in the tyrosine kinase domain of the insulin receptor associated with insulin resistance in an obese woman. J Clin Endocrinol Metab. 1991 Oct;73(4):894-901.
1963473	Moller DE, Yokota A, Ginsberg-Fellner F, Flier JS: Functional properties of a naturally occurring Trp1200----Ser1200 mutation of the insulin receptor. Mol Endocrinol. 1990 Aug;4(8):1183-91.
2002058	Kusari J, Takata Y, Hatada E, Freidenberg G, Kolterman O, Olefsky JM: Insulin resistance and diabetes due to different mutations in the tyrosine kinase domain of both insulin receptor gene alleles. J Biol Chem. 1991 Mar 15;266(8):5260-7.
2040394	O'Rahilly S, Choi WH, Patel P, Turner RC, Flier JS, Moller DE: Detection of mutations in insulin-receptor gene in NIDDM patients by analysis of single-stranded conformation polymorphisms. Diabetes. 1991 Jun;40(6):777-82.
2121734	Kadowaki T, Kadowaki H, Accili D, Taylor SI: Substitution of lysine for asparagine at position 15 in the alpha-subunit of the human insulin receptor. A mutation that impairs transport of receptors to the cell surface and decreases the affinity of insulin binding. J Biol Chem. 1990 Nov 5;265(31):19143-50.
2168397	Moller DE, Yokota A, White MF, Pazianos AG, Flier JS: A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance. J Biol Chem. 1990 Sep 5;265(25):14979-85.
2210055	Seino S, Seino M, Bell GI: Human insulin-receptor gene. Partial sequence and amplification of exons by polymerase chain reaction. Diabetes. 1990 Jan;39(1):123-8.
2211730	Xu QY, Paxton RJ, Fujita-Yamaguchi Y: Substructural analysis of the insulin receptor by microsequence analyses of limited tryptic fragments isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in the absence or presence of dithiothreitol. J Biol Chem. 1990 Oct 25;265(30):18673-81.
2280779	McKeon C, Moncada V, Pham T, Salvatore P, Kadowaki T, Accili D, Taylor SI: Structural and functional analysis of the insulin receptor promoter. Mol Endocrinol. 1990 Apr;4(4):647-56.
2365819	Kadowaki T, Kadowaki H, Rechler MM, Serrano-Rios M, Roth J, Gorden P, Taylor SI: Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance. J Clin Invest. 1990 Jul;86(1):254-64.
2369896	Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DA: Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J. 1990 Aug;9(8):2409-13.
2479553	Klinkhamer MP, Groen NA, van der Zon GC, Lindhout D, Sandkuyl LA, Krans HM, Moller W, Maassen JA: A leucine-to-proline mutation in the insulin receptor in a family with insulin resistance. EMBO J. 1989 Sep;8(9):2503-7.
2538124	Seino S, Bell GI: Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun. 1989 Feb 28;159(1):312-6.
2544997	Taira M, Taira M, Hashimoto N, Shimada F, Suzuki Y, Kanatsuka A, Nakamura F, Ebina Y, Tatibana M, Makino H, et al.: Human diabetes associated with a deletion of the tyrosine kinase domain of the insulin receptor. Science. 1989 Jul 7;245(4913):63-6.
2544998	Odawara M, Kadowaki T, Yamamoto R, Shibasaki Y, Tobe K, Accili D, Bevins C, Mikami Y, Matsuura N, Akanuma Y, et al.: Human diabetes associated with a mutation in the tyrosine kinase domain of the insulin receptor. Science. 1989 Jul 7;245(4913):66-8.
2566545	Elbein SC: Molecular and clinical characterization of an insertional polymorphism of the insulin-receptor gene. Diabetes. 1989 Jun;38(6):737-43.
2777789	Tewari DS, Cook DM, Taub R: Characterization of the promoter region and 3' end of the human insulin receptor gene. J Biol Chem. 1989 Sep 25;264(27):16238-45.
2806055	Araki E, Shimada F, Fukushima H, Mori M, Shichiri M, Ebina Y: Characterization of the promoter region of the human insulin receptor gene. Diabetes Res Clin Pract. 1989;7 Suppl 1:S31-3.
2834824	Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, Kadowaki H, Beitz L, McKeon C, Taylor SI: Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science. 1988 May 6;240(4853):787-90.
2842060	White MF, Livingston JN, Backer JM, Lauris V, Dull TJ, Ullrich A, Kahn CR: Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity. Cell. 1988 Aug 26;54(5):641-9.
2859121	Ebina Y, Ellis L, Jarnagin K, Edery M, Graf L, Clauser E, Ou JH, Masiarz F, Kan YW, Goldfine ID, et al.: The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell. 1985 Apr;40(4):747-58.
2983222	Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M, et al.: Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature. 1985 Feb 28-Mar 6;313(6005):756-61.
3101064	Ebina Y, Araki E, Taira M, Shimada F, Mori M, Craik CS, Siddle K, Pierce SB, Roth RA, Rutter WJ: Replacement of lysine residue 1030 in the putative ATP-binding region of the insulin receptor abolishes insulin- and antibody-stimulated glucose uptake and receptor kinase activity. Proc Natl Acad Sci U S A. 1987 Feb;84(3):704-8.
3166375	Tavare JM, Denton RM: Studies on the autophosphorylation of the insulin receptor from human placenta. Analysis of the sites phosphorylated by two-dimensional peptide mapping. Biochem J. 1988 Jun 1;252(2):607-15.
3283938	Yoshimasa Y, Seino S, Whittaker J, Kakehi T, Kosaki A, Kuzuya H, Imura H, Bell GI, Steiner DF: Insulin-resistant diabetes due to a point mutation that prevents insulin proreceptor processing. Science. 1988 May 6;240(4853):784-7.
3447155	Fujita-Yamaguchi Y, Hawke DH, Shively JE, Choi S: Partial amino acid sequence analyses of human placental insulin receptor. Protein Seq Data Anal. 1987;1(1):3-6.
3680248	Araki E, Shimada F, Uzawa H, Mori M, Ebina Y: Characterization of the promoter region of the human insulin receptor gene. Evidence for promoter activity. J Biol Chem. 1987 Nov 25;262(33):16186-91.
7538143	Longo N, Langley SD, Griffin LD, Elsas LJ: Two mutations in the insulin receptor gene of a patient with leprechaunism: application to prenatal diagnosis. J Clin Endocrinol Metab. 1995 May;80(5):1496-501.
7559478	He W, O'Neill TJ, Gustafson TA: Distinct modes of interaction of SHC and insulin receptor substrate-1 with the insulin receptor NPEY region via non-SH2 domains. J Biol Chem. 1995 Oct 6;270(40):23258-62.
7657032	Kan M, Kanai F, Iida M, Jinnouchi H, Todaka M, Imanaka T, Ito K, Nishioka Y, Ohnishi T, Kamohara S, et al.: Frequency of mutations of insulin receptor gene in Japanese patients with NIDDM. Diabetes. 1995 Sep;44(9):1081-6.
7815442	Hone J, Accili D, al-Gazali LI, Lestringant G, Orban T, Taylor SI: Homozygosity for a new mutation (Ile119-->Met) in the insulin receptor gene in five sibs with familial insulin resistance. J Med Genet. 1994 Sep;31(9):715-6.
7983039	Imamura T, Takata Y, Sasaoka T, Takada Y, Morioka H, Haruta T, Sawa T, Iwanishi M, Hu YG, Suzuki Y, et al.: Two naturally occurring mutations in the kinase domain of insulin receptor accelerate degradation of the insulin receptor and impair the kinase activity. J Biol Chem. 1994 Dec 9;269(49):31019-27.
7997262	Hubbard SR, Wei L, Ellis L, Hendrickson WA: Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 1994 Dec 22-29;372(6508):746-54.
8082780	Moritz W, Froesch ER, Boni-Schnetzler M: Functional properties of a heterozygous mutation (Arg1174-->Gln) in the tyrosine kinase domain of the insulin receptor from a type A insulin resistant patient. FEBS Lett. 1994 Sep 5;351(2):276-80.
8096518	Cama A, de la Luz Sierra M, Quon MJ, Ottini L, Gorden P, Taylor SI: Substitution of glutamic acid for alanine 1135 in the putative "catalytic loop" of the tyrosine kinase domain of the human insulin receptor. A mutation that impairs proteolytic processing into subunits and inhibits receptor tyrosine kinase activity. J Biol Chem. 1993 Apr 15;268(11):8060-9.
8188715	van der Vorm ER, Kuipers A, Kielkopf-Renner S, Krans HM, Moller W, Maassen JA: A mutation in the insulin receptor that impairs proreceptor processing but not insulin binding. J Biol Chem. 1994 May 13;269(19):14297-302.
8242067	Carrera P, Cordera R, Ferrari M, Cremonesi L, Taramelli R, Andraghetti G, Carducci C, Dozio N, Pozza G, Taylor SI, et al.: Substitution of Leu for Pro-193 in the insulin receptor in a patient with a genetic form of severe insulin resistance. Hum Mol Genet. 1993 Sep;2(9):1437-41.
8243830	Haruta T, Takata Y, Iwanishi M, Maegawa H, Imamura T, Egawa K, Itazu T, Kobayashi M: Ala1048-->Asp mutation in the kinase domain of insulin receptor causes defective kinase activity and insulin resistance. Diabetes. 1993 Dec;42(12):1837-44.
8288049	Moller DE, Cohen O, Yamaguchi Y, Assiz R, Grigorescu F, Eberle A, Morrow LA, Moses AC, Flier JS: Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes. 1994 Feb;43(2):247-55.
8314008	Krook A, Kumar S, Laing I, Boulton AJ, Wass JA, O'Rahilly S: Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes. 1994 Mar;43(3):357-68.
8326490	al-Gazali LI, Khalil M, Devadas K: A syndrome of insulin resistance resembling leprechaunism in five sibs of consanguineous parents. J Med Genet. 1993 Jun;30(6):470-5.
8388389	Lebrun C, Baron V, Kaliman P, Gautier N, Dolais-Kitabgi J, Taylor S, Accili D, Van Obberghen E: Antibodies to the extracellular receptor domain restore the hormone-insensitive kinase and conformation of the mutant insulin receptor valine 382. J Biol Chem. 1993 May 25;268(15):11272-7.
8390949	Iwanishi M, Haruta T, Takata Y, Ishibashi O, Sasaoka T, Egawa K, Imamura T, Naitou K, Itazu T, Kobayashi M: A mutation (Trp1193-->Leu1193) in the tyrosine kinase domain of the insulin receptor associated with type A syndrome of insulin resistance. Diabetologia. 1993 May;36(5):414-22.
8419945	Longo N, Langley SD, Griffin LD, Elsas LJ: Activation of glucose transport by a natural mutation in the human insulin receptor. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):60-4.
8432414	Elbein SC, Sorensen LK, Schumacher MC: Methionine for valine substitution in exon 17 of the insulin receptor gene in a pedigree with familial NIDDM. Diabetes. 1993 Mar;42(3):429-34.
8458533	van der Vorm ER, Kuipers A, Bonenkamp JW, Kleijer WJ, Van Maldergem L, Herwig J, Maassen JA: Patients with lipodystrophic diabetes mellitus of the Seip-Berardinelli type, express normal insulin receptors. Diabetologia. 1993 Feb;36(2):172-4.
8636294	Desbois-Mouthon C, Sert-Langeron C, Magre J, Oreal E, Blivet MJ, Flori E, Besmond C, Capeau J, Caron M: Deletion of Asn281 in the alpha-subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization. J Clin Endocrinol Metab. 1996 Feb;81(2):719-27.
8890729	Moritz W, Boni-Schnetzler M, Stevens W, Froesch ER, Levy JR: In-frame exon 2 deletion in insulin receptor RNA in a family with extreme insulin resistance in association with defective insulin binding: a case report. Eur J Endocrinol. 1996 Sep;135(3):357-63.
9175790	Rouard M, Macari F, Bouix O, Lautier C, Brun JF, Lefebvre P, Renard E, Bringer J, Jaffiol C, Grigorescu F: Identification of two novel insulin receptor mutations, Asp59Gly and Leu62Pro, in type A syndrome of extreme insulin resistance. Biochem Biophys Res Commun. 1997 May 29;234(3):764-8.
9199575	Hansen L, Hansen T, Clausen JO, Echwald SM, Urhammer SA, Rasmussen SK, Pedersen O: The Val985Met insulin-receptor variant in the Danish Caucasian population: lack of associations with non-insulin-dependent diabetes mellitus or insulin resistance. Am J Hum Genet. 1997 Jun;60(6):1532-5.
9249867	Desbois-Mouthon C, Girodon E, Ghanem N, Caron M, Pennerath A, Conteville P, Magre J, Besmond C, Goossens M, Capeau J, Amselem S: Molecular analysis of the insulin receptor gene for prenatal diagnosis of leprechaunism in two families. Prenat Diagn. 1997 Jul;17(7):657-63.
9299395	Kadowaki H, Takahashi Y, Ando A, Momomura K, Kaburagi Y, Quin JD, MacCuish AC, Koda N, Fukushima Y, Taylor SI, Akanuma Y, Yazaki Y, Kadowaki T: Four mutant alleles of the insulin receptor gene associated with genetic syndromes of extreme insulin resistance. Biochem Biophys Res Commun. 1997 Aug 28;237(3):516-20.
9312016	Hubbard SR: Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 1997 Sep 15;16(18):5572-81.
9703342	Whitehead JP, Soos MA, Jackson R, Tasic V, Kocova M, O'Rahilly S: Multiple molecular mechanisms of insulin receptor dysfunction in a patient with Donohue syndrome. Diabetes. 1998 Aug;47(8):1362-4.

# Drug_Target_6_HGNC_ID:
HGNC:6091

# Drug_Target_6_HPRD_ID:
00975

# Drug_Target_6_ID:
36

# Drug_Target_6_Locus:
19p13.3-p13.2

# Drug_Target_6_Molecular_Weight:
156308

# Drug_Target_6_Name:
Insulin receptor

# Drug_Target_6_Number_of_Residues:
1382

# Drug_Target_6_PDB_ID:
1IRK

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00041	fn3
PF00757	Furin-like
PF01030	Recep_L_domain
PF07714	Pkinase_Tyr

# Drug_Target_6_Protein_Sequence:
>Insulin receptor precursor
MGTGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL
QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL
VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE
ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL
GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG
CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC
TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL
EIGNYSFYALDNQNLRQLWDWSKHNLTTTQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE
RNDIALKTNGDKASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ
NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS
DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE
RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL
KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF
PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV
SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV
SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG
PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR
EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG
FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA
AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV
RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN
CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME
FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN
PS

# Drug_Target_6_Reaction:
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate

# Drug_Target_6_Signals:
1-27

# Drug_Target_6_Specific_Function:
This receptor binds insulin and has a tyrosine-protein kinase activity. Isoform Short has a higher affinity for insulin. Mediates the metabolic functions of insulin. Binding to insulin stimulates association of the receptor with downstream mediators including IRS1 and phosphatidylinositol 3'-kinase (PI3K). Can activate PI3K either directly by binding to the p85 regulatory subunit, or indirectly via IRS1

# Drug_Target_6_SwissProt_ID:
P06213

# Drug_Target_6_SwissProt_Name:
INSR_HUMAN

# Drug_Target_6_Synonyms:
CD220 antigen
EC 2.7.10.1
IR
Insulin receptor precursor

# Drug_Target_6_Theoretical_pI:
6.18

# Drug_Target_6_Transmembrane_Regions:
957-979

# Drug_Target_7_Cellular_Location:
Endoplasmic reticulum membrane

# Drug_Target_7_Chromosome_Location:
1

# Drug_Target_7_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
AK291314

# Drug_Target_7_GenBank_ID_Protein:
158256064

# Drug_Target_7_GeneCard_ID:
ATP2A1

# Drug_Target_7_Gene_Name:
ATP2A1

# Drug_Target_7_Gene_Sequence:
>2985 bp
ATGGAGGCCGCTCATGCTAAAACCACGGAGGAATGTTTGGCCTATTTTGGGGTGAGTGAG
ACCACGGGCCTCACCCCGGACCAAGTTAAGCGGAATCTGGAGAAATACGGCCTCAATGAG
CTCCCTGCTGAGGAAGGGAAGACCCTGTGGGAGCTGGTGATAGAGCAGTTTGAAGACCTC
CTGGTGCGGATTCTCCTCCTGGCCGCATGCATTTCCTTCGTGCTGGCCTGGTTTGAGGAA
GGTGAAGAGACCATCACTGCCTTTGTTGAACCCTTTGTCATCCTCTTGATCCTCATTGCC
AATGCCATCGTGGGGGTTTGGCAGGAGCGGAACGCAGAGAACGCCATCGAGGCCCTGAAG
GAGTATGAGCCAGAGATGGGGAAGGTCTACCGGGCTGACCGCAAGTCAGTGCAAAGGATC
AAGGCTCGGGACATCGTCCCTGGGGACATCGTGGAGGTGGCTGTGGGGGACAAAGTCCCT
GCAGACATCCGAATCCTCGCCATCAAATCCACCACGCTGCGGGTTGACCAGTCCATCCTG
ACAGGCGAGTCTGTATCTGTCATCAAACACACGGAGCCCGTTCCTGACCCCCGAGCTGTC
AACCAGGACAAGAAGAACATGCTTTTCTCGGGCACCAACATTGCAGCCGGCAAGGCCTTG
GGCATCGTGGCCACCACTGGTGTGGGCACCGAGATTGGGAAGATCCGAGACCAAATGGCT
GCCACAGAACAGGACAAGACCCCCTTGCAGCAGAAGCTGGATGAGTTTGGGGAGCAGCTC
TCCAAGGTCATCTCCCTCATCTGTGTGGCTGTCTGGCTTATCAACATTGGCCACTTCAAC
GACCCCGTCCATGGGGGCTCCTGGTTCCGCGGGGCCATCTACTACTTTAAGATTGCCGTG
GCCTTGGCTGTGGCTGCCATCCCCGAAGGTCTTCCTGCAGTCATCACCACCTGCCTGGCC
CTGGGTACCCGTCGGATGGCAAAGAAGAATGCCATTGTAAGAAGCTTGCCCTCCGTAGAG
ACCCTGGGCTGCACCTCTGTCATCTGTTCCGACAAGACAGGCACCCTCACCACCAACCAG
ATGTCTGTCTGCAAGATGTTTATCATTGACAAGGTGGATGGGGACATCTGCCTCCTGAAT
GAGTTCTCCATCACCGGCTCCACTTACGCTCCAGAGGGAGAGGTCTTGAAGAATGATAAG
CCAGTCCGGCCAGGGCAGTATGACGGGCTGGTGGAGCTGGCCACCATCTGTGCCCTCTGC
AATGACTCCTCCTTGGACTTCAACGAGGCCAAAGGTGTCTATGAGAAGGTCGGCGAGGCC
ACCGAGACAGCACTCACCACCCTGGTGGAGAAGATGAATGTGTTCAACACGGATGTGAGA
AGCCTCTCGAAGGTGGAGAGAGCCAACGCCTGCAACTCGGTGATCCGCCAGCTAATGAAG
AAGGAATTCACCCTGGAGTTCTCCCGAGACAGAAAGTCCATGTCTGTCTATTGCTCCCCA
GCCAAATCTTCCCGGGCTGCTGTGGGCAACAAGATGTTTGTCAAGGGTGCCCCTGAGGGC
GTCATCGACCGCTGTAACTATGTGCGAGTTGGCACCACCCGGGTGCCACTGACGGGGCCG
GTGAAGGAAAAGATCATGGCGGTGATCAAGGAGTGGGGCACTGGCCGGGACACCCTGCGC
TGCTTGGCCCTGGCCACCCGGGACACCCCCCCGAAGCGAGAGGAAATGGTCCTGGATGAC
TCTGCCAGGTTCCTGGAGTATGAGACGGACCTGACATTCGTGGGTGTAGTGGGCATGCTG
GACCCTCCGCGCAAGGAGGTCACGGGCTCCATCCAGCTGTGCCGTGACGCCGGGATCCGG
GTGATCATGATCACTGGGGACAACAAGGGCACAGCCATTGCCATCTGCCGGCGAATTGGC
ATCTTTGGGGAGAACGAGGAGGTGGCCGATCGCGCCTACACGGGCCGAGAGTTCGACGAC
CTGCCCCTGGCTGAACAGCGGGAAGCCTGCCGACGTGCCTGCTGCTTCGCCCGTGTGGAG
CCCTCGCACAAGTCCAAGATTGTGGAGTACCTGCAGTCCTACGATGAGATCACAGCCATG
ACAGGTGATGGCGTCAATGACGCCCCTGCCCTGAAGAAGGCTGAGATTGGCATTGCCATG
GGATCTGGCACTGCCGTGGCCAAGACTGCCTCTGAGATGGTGCTGGCTGACGACAACTTC
TCCACCATCGTAGCTGCTGTGGAGGAGGGCCGCGCCATCTACAACAACATGAAGCAGTTC
ATCCGCTACCTCATTTCCTCCAACGTGGGCGAGGTGGTCTGTATCTTCCTGACCGCTGCC
CTGGGGCTGCCTGAGGCCCTGATCCCGGTGCAGCTGCTATGGGTGAACTTGGTGACCGAC
GGGCTCCCAGCCACAGCCCTGGGCTTCAACCCACCAGACCTGGACATCATGGACCGCCCC
CCCCGGAGCCCCAAGGAGCCCCTCATCAGTGGCTGGCTCTTCTTCCGCTACATGGCAATC
GGGGGCTATGTGGGTGCAGCCACCGTGGGAGCAGCTGCCTGGTGGTTCCTGTACGCTGAG
GATGGGCCTCATGTCAACTACAGCCAGCTGACTCACTTCATGCAGTGCACCGAGGACAAC
ACCCACTTTGAGGGCATAGACTGTGAGGTCTTCGAGGCCCCCGAGCCCATGACCATGGCC
CTGTCCGTGCTGGTGACCATCGAGATGTGCAATGCACTGAACAGCCTGTCCGAGAACCAG
TCCCTGCTGCGGATGCCACCCTGGGTGAACATCTGGCTGCTGGGCTCCATCTGCCTCTCC
ATGTCCCTGCACTTCCTCATCCTCTATGTTGACCCCCTGCCGATGATCTTCAAGCTCCGG
GCCCTGGACCTCACCCAGTGGCTCATGGTCCTCAAGATCTCACTGCCAGTCATTGGGCTC
GACGAAATCCTCAAGTTCGTTGCTCGGAACTACCTAGAGGGATAA

# Drug_Target_7_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_7_General_References:
10914677	Odermatt A, Barton K, Khanna VK, Mathieu J, Escolar D, Kuntzer T, Karpati G, MacLennan DH: The mutation of Pro789 to Leu reduces the activity of the fast-twitch skeletal muscle sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA1) and is associated with Brody disease. Hum Genet. 2000 May;106(5):482-91.
11438520	Daiho T, Yamasaki K, Saino T, Kamidochi M, Satoh K, Iizuka H, Suzuki H: Mutations of either or both Cys876 and Cys888 residues of sarcoplasmic reticulum Ca2+-ATPase result in a complete loss of Ca2+ transport activity without a loss of Ca2+-dependent ATPase activity. Role of the CYS876-CYS888 disulfide bond. J Biol Chem. 2001 Aug 31;276(35):32771-8. Epub 2001 Jul 3.
14702039	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.
8825625	Zhang Y, Fujii J, Phillips MS, Chen HS, Karpati G, Yee WC, Schrank B, Cornblath DR, Boylan KB, MacLennan DH: Characterization of cDNA and genomic DNA encoding SERCA1, the Ca(2+)-ATPase of human fast-twitch skeletal muscle sarcoplasmic reticulum, and its elimination as a candidate gene for Brody disease. Genomics. 1995 Dec 10;30(3):415-24.

# Drug_Target_7_HGNC_ID:
GNC:811

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
6390

# Drug_Target_7_Locus:
16p12.1

# Drug_Target_7_Molecular_Weight:
110251.4

# Drug_Target_7_Name:
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1

# Drug_Target_7_Number_of_Residues:
1001

# Drug_Target_7_PDB_ID:
1XP5

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00122	E1-E2_ATPase
PF00689	Cation_ATPase_C
PF00690	Cation_ATPase_N
PF00702	Hydrolase

# Drug_Target_7_Protein_Sequence:
>Sarcoplasmic/endoplasmic reticulum calcium ATPase 1
MEAAHAKTTEECLAYFGVSETTGLTPDQVKRNLEKYGLNELPAEEGKTLWELVIEQFEDL
LVRILLLAACISFVLAWFEEGEETITAFVEPFVILLILIANAIVGVWQERNAENAIEALK
EYEPEMGKVYRADRKSVQRIKARDIVPGDIVEVAVGDKVPADIRILAIKSTTLRVDQSIL
TGESVSVIKHTEPVPDPRAVNQDKKNMLFSGTNIAAGKALGIVATTGVGTEIGKIRDQMA
ATEQDKTPLQQKLDEFGEQLSKVISLICVAVWLINIGHFNDPVHGGSWFRGAIYYFKIAV
ALAVAAIPEGLPAVITTCLALGTRRMAKKNAIVRSLPSVETLGCTSVICSDKTGTLTTNQ
MSVCKMFIIDKVDGDICLLNEFSITGSTYAPEGEVLKNDKPVRPGQYDGLVELATICALC
NDSSLDFNEAKGVYEKVGEATETALTTLVEKMNVFNTDVRSLSKVERANACNSVIRQLMK
KEFTLEFSRDRKSMSVYCSPAKSSRAAVGNKMFVKGAPEGVIDRCNYVRVGTTRVPLTGP
VKEKIMAVIKEWGTGRDTLRCLALATRDTPPKREEMVLDDSARFLEYETDLTFVGVVGML
DPPRKEVTGSIQLCRDAGIRVIMITGDNKGTAIAICRRIGIFGENEEVADRAYTGREFDD
LPLAEQREACRRACCFARVEPSHKSKIVEYLQSYDEITAMTGDGVNDAPALKKAEIGIAM
GSGTAVAKTASEMVLADDNFSTIVAAVEEGRAIYNNMKQFIRYLISSNVGEVVCIFLTAA
LGLPEALIPVQLLWVNLVTDGLPATALGFNPPDLDIMDRPPRSPKEPLISGWLFFRYMAI
GGYVGAATVGAAAWWFLYAEDGPHVNYSQLTHFMQCTEDNTHFEGIDCEVFEAPEPMTMA
LSVLVTIEMCNALNSLSENQSLLRMPPWVNIWLLGSICLSMSLHFLILYVDPLPMIFKLR
ALDLTQWLMVLKISLPVIGLDEILKFVARNYLEDPEDERRK

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen. Contributes to calcium sequestration involved in muscular excitation/contraction

# Drug_Target_7_SwissProt_ID:
O14983

# Drug_Target_7_SwissProt_Name:
AT2A1_HUMAN

# Drug_Target_7_Synonyms:
Calcium pump 1
Calcium-transporting ATPase sarcoplasmic reticulum type, fast twitch skeletal muscle isoform
Endoplasmic reticulum class 1/2 Ca(2+) ATPase
SERCA1
SR Ca(2+)-ATPase 1

# Drug_Target_7_Theoretical_pI:
4.80

# Drug_Target_7_Transmembrane_Regions:
49-69
90-110
254-273
296-313
758-777
788-808
829-851
898-917
931-949
965-985

# Drug_Target_8_Cellular_Location:
Cytoplasm

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
PDXK

# Drug_Target_8_GenBank_ID_Gene:
U89606

# Drug_Target_8_GenBank_ID_Protein:
1946349

# Drug_Target_8_GeneCard_ID:
PDXK

# Drug_Target_8_Gene_Name:
PDXK

# Drug_Target_8_Gene_Sequence:
>939 bp
ATGGAGGAGGAGTGCCGGGTGCTCTCCATACAGAGCCACGTCATCCGCGGCTACGTGGGC
AACCGGGCGGCCACGTTCCCGCTGCAGGTTTTGGGATTTGAGATTGACGCGGTGAACTCT
GTCCAGTTTTCAAACCACACAGGCTATGCCCACTGGAAGGGCCAAGTGCTGAATTCAGAT
GAGCTCCAGGAGTTGTACGAAGGCCTGAGGCTGAACAACATGAATAAATATGACTACGTG
CTCACAGGTTATACGAGGGACAAGTCGTTCCTGGCCATGGTGGTGGACATTGTGCAGGAG
CTGAAGCAGCAGAACCCCAGGCTGGTGTACGTGTGTGATCCAGTCTTGGGTGACAAGTGG
GACGGCGAAGGCTCGATGTACGTCCCGGAGGACCTCCTTCCCGTCTACAAAGAAAAAGTG
GTGCCGCTTGCAGACATTATCACGCCCAACCAGTTTGAGGCCGAGTTACTGAGTGGCCGG
AAGATCCACAGCCAGGAGGAAGCCTTGCGGGTGATGGACATGCTGCACTCTATGGGCCCC
GACACCGTGGTCATCACCAGCTCCGACCTGCCCTCCCCGCAGGGCAGCAACTACCTGATT
GTGCTGGGGAGTCAGAGGAGGAGGAATCCCGCTGGCTCCGTGGTGATGGAACGCATCCGG
ATGGACATTCGCAAAGTGGACGCCGTCTTTGTGGGCACTGGGGACCTGTTTGCTGCCATG
CTCCTGGCGTGGACACACAAGCACCCCAATAACCTCAAGGTGGCCTGTGAGAAGACCGTG
TCTACCTTGCACCACGTTCTGCAGAGGACCATCCAGTGTGCAAAAGCCCAGGCCGGGGAA
GGAGTGAGGCCCAGCCCCATGCAGCTGGAGCTGCGGATGGTGCAGAGCAAAAGGGACATC
GAGGACCCAGAGATCGTCGTCCAGGCCACGGTGCTGTGA

# Drug_Target_8_General_Function:
Coenzyme transport and metabolism

# Drug_Target_8_General_References:
10830953	Hattori M, Fujiyama A, Taylor TD, Watanabe H, Yada T, Park HS, Toyoda A, Ishii K, Totoki Y, Choi DK, Groner Y, Soeda E, Ohki M, Takagi T, Sakaki Y, Taudien S, Blechschmidt K, Polley A, Menzel U, Delabar J, Kumpf K, Lehmann R, Patterson D, Reichwald K, Rump A, Schillhabel M, Schudy A, Zimmermann W, Rosenthal A, Kudoh J, Schibuya K, Kawasaki K, Asakawa S, Shintani A, Sasaki T, Nagamine K, Mitsuyama S, Antonarakis SE, Minoshima S, Shimizu N, Nordsiek G, Hornischer K, Brant P, Scharfe M, Schon O, Desario A, Reichelt J, Kauer G, Blocker H, Ramser J, Beck A, Klages S, Hennig S, Riesselmann L, Dagand E, Haaf T, Wehrmeyer S, Borzym K, Gardiner K, Nizetic D, Francis F, Lehrach H, Reinhardt R, Yaspo ML: The DNA sequence of human chromosome 21. Nature. 2000 May 18;405(6784):311-9.
10987144	Lee HS, Moon BJ, Choi SY, Kwon OS: Human pyridoxal kinase: overexpression and properties of the recombinant enzyme. Mol Cells. 2000 Aug 31;10(4):452-9.
9099727	Hanna MC, Turner AJ, Kirkness EF: Human pyridoxal kinase. cDNA cloning, expression, and modulation by ligands of the benzodiazepine receptor. J Biol Chem. 1997 Apr 18;272(16):10756-60.

# Drug_Target_8_HGNC_ID:
HGNC:8819

# Drug_Target_8_HPRD_ID:
01526

# Drug_Target_8_ID:
48

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
35103

# Drug_Target_8_Name:
Pyridoxal kinase

# Drug_Target_8_Number_of_Residues:
312

# Drug_Target_8_PDB_ID:
1RFV

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00294	PfkB

# Drug_Target_8_Protein_Sequence:
>Pyridoxal kinase
MEEECRVLSIQSHVIRGYVGNRAATFPLQVLGFEIDAVNSVQFSNHTGYAHWKGQVLNSD
ELQELYEGLRLNNMNKYDYVLTGYTRDKSFLAMVVDIVQELKQQNPRLVYVCDPVLGDKW
DGEGSMYVPEDLLPVYKEKVVPLADIITPNQFEAELLSGRKIHSQEEALRVMDMLHSMGP
DTVVITSSDLPSPQGSNYLIVLGSQRRRNPAGSVVMERIRMDIRKVDAVFVGTGDLFAAM
LLAWTHKHPNNLKVACEKTVSTLHHVLQRTIQCAKAQAGEGVRPSPMQLELRMVQSKRDI
EDPEIVVQATVL

# Drug_Target_8_Reaction:
ATP + pyridoxal = ADP + pyridoxal 5'-phosphate

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Required for synthesis of pyridoxal-5-phosphate from vitamin B6

# Drug_Target_8_SwissProt_ID:
O00764

# Drug_Target_8_SwissProt_Name:
PDXK_HUMAN

# Drug_Target_8_Synonyms:
EC 2.7.1.35
Pyridoxine kinase

# Drug_Target_8_Theoretical_pI:
6.05

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
Not Available

# Drug_Target_9_GenBank_ID_Protein:
Not Available

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
PGK1

# Drug_Target_9_Gene_Sequence:
Not Available

# Drug_Target_9_General_Function:
Not Available

# Drug_Target_9_General_References:
Not Available

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
6964

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
Not Available

# Drug_Target_9_Name:
Phosphoglycerate kinase 1

# Drug_Target_9_Number_of_Residues:
0

# Drug_Target_9_PDB_ID:
Not Available

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
Not Available

# Drug_Target_9_Protein_Sequence:
Not Available

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
Not Available

# Drug_Target_9_Specific_Function:
Not Available

# Drug_Target_9_SwissProt_ID:
P00558

# Drug_Target_9_SwissProt_Name:
PGK1_HUMAN

# Drug_Target_9_Synonyms:
Not Available

# Drug_Target_9_Theoretical_pI:
Not Available

# Drug_Target_9_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB03909
